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ABSTRACT

Due to the pressing need for new disease-modifying drugs for Alzheimer’s disease (AD),
new treatment strategies and alternative drug targets are currently being heavily researched. One
such strategy is to modulate protein kinases such as cyclin-dependent kinase 1 (CDK1), cyclindependent kinase 5 (CDK5), glycogen synthase kinase-3 (GSK-3α and GSK-3β), and the protein
kinase RNA-like endoplasmic reticulum kinase (PERK). AD intervention by reduction of
amyloid beta (Aβ) levels is also possible through development of protein kinase C-epsilon (PKCε) activators to recover α-secretase levels and decrease toxic Aβ levels, thereby restoring
synaptogenesis and cognitive function. In this way, we aim to develop new AD drugs by
targeting kinases that participate in AD pathophysiology.
In our studies, comparative modeling was performed to construct 3D models for kinases
whose crystal structures have not yet been identified. The information from structurally similar
proteins was used to define the amino acid residues in the ATP binding site as well as other
important sites and motifs. We searched for the common structural motifs and domains of GSK3β, CDK5 and PERK. Further, we identified the conserved water molecules in GSK-3β, CDK5
and PERK through calculation of the degree of water conservation. We investigated the proteinligand interaction profiles of CDK1, CDK5, GSK-3α, GSK-3β and PERK based on molecular
dynamics (MD) simulations, which provided a time-dependent demonstration of the interactions
and contacts for each ligand. In addition, we explored the protein-protein interactions between
CDK5 and p25. Small molecules which target this interaction may offer a prospective
ii

therapeutic benefit for AD. In order to identify new modulators for protein kinase targets in AD,
we implemented three virtual screening protocols. The first protocol was a combined ligand- and
protein structure-based approach to find new PERK inhibitors. In the second protocol, protein
structure-based virtual screening was applied to find multiple-kinase inhibitors through parallel
docking simulations into validated models of CDK1, CDK5 and GSK-3 kinases. In the third
protocol, we searched for potential activators of PKC-ε based on the structure of its C1B domain.
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CHAPTER 1. INTRODUCTION
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1.1. Alzheimer’s disease
Alzheimer’s disease (AD) is a disease of the brain, which is characterized by
deterioration in perception, physical function, and behavior1. About 25 million people in the
world are reported to have dementia2, 3 (weakening of intellectual abilities that rigorously limits
activities of daily life), with the most common type of dementia being AD4. Approximately 6.8
million individuals in the United States are living with dementia, and about 5.3 million have
been diagnosed with AD5 (Figure 1.1). It is the sixth leading cause of all deaths and the ﬁfth
leading cause of death in people aged ≥ 65 years in USA6. As the elderly population remains to
increase, these figures are expected to nearly double by 2020, and quadruple by 2040. AD is
predicted to affect 1 in 85 people worldwide by 20507.

Figure 1.1. Number of people age 65 and older in the U.S divided by age group8. Population
with AD, 2010 to 2050. Reprinted from: Alzheimer's & Dementia, 11(3), Alzheimer’s
Association, 2015, Alzheimer's disease facts and figures, 332-384, Copyright (2015), with
permission from Elsevier.
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AD has arisen as a serious public health concern, placing a huge burden on the
individual, family, community, and health care resources9. The cost of caring for the growing
number of people with dementia remains to grow and the World Health Organization (WHO)
estimated that, in the population over 60 years old, dementia contributes to 11.2% of years spent
living with a disability—more than stroke, cardiovascular disease, or cancer. Based on the
current expenses of $226 billion in 2015, AD is considered the most expensive disease in the
USA10. In 2015, one of each five Medicare dollars was spent on AD, and by 2050 AD is
expected to cost $1.1 trillion per year11, 12. Therefore, AD will cause a 500% increase in annual
Medicare and Medicaid spending by 205013.

1.1.1. Pathogenesis
Out of all the theories developed to elucidate the pathogenesis of AD, the most broadly
accepted are the amyloid beta (Aβ) and the tau hyperphosphorylation hypothesis14,

15

. This

caused the therapies under exploration to target exclusively Aβ production/aggregation and
tauopathies. According to the Aβ hypothesis, an unusual overproduction of Aβ (a 42-amino acid
peptide) is responsible for the neurotoxicity, which leads to senile (neuritic) plaque formation
and neuronal death16-18. Aβ is derived from the transmembrane (TM) precursor, amyloid
precursor protein (APP), by the action of β-secretase and γ-secretase19. The β-secretase enzyme,
or BACE-1 (βeta-site APP-cleaving enzyme 1), catalyzes the first cleavage that produces soluble
APP-β and a C-terminal membrane-bound region, C99, which is the immediate substrate for the
γ-secretase enzyme20-22 (Figure 1.2). There has been intense research on Aβ peptide, and the
polymerization of Aβ into neurotoxic aggregates is considered a key event in the pathological
cascade that results in AD.
3

Figure 1.2. The breakup of APP by secretase enzymes23. Under normal conditions, APP is
favorably cleaved by α-secretase. In AD, β-secretase and then γ-secretase cleave APP to generate
the neurotoxic Aβ peptides. The plaques are then formed by the aggregation of the Aβ peptides
into oligomeric aggregates. Reprinted by permission from Macmillan Publishers Ltd: [Nature
Reviews] (Götz J and Ittner LM, (7): 532-44, Copyright (2008).

Consistent with the tau hyperphosphorylation hypothesis, tau protein, a microtubuleconnected protein that strengthens the neuronal cytoskeleton, is aberrantly hyperphosphorylated
and groups into neurofibrillary tangles (NFT), leading to neuronal death24-26 (Figure 1.3). The
balance between the activities of tau kinases and phosphatases controls the extent of tau
phosphorylation, so disturbance of this balance causes atypical tau phosphorylation, resulting in
reducing the affinity of tau for microtubules. Tau aggregation is strongly linked to the severity of
AD more than Aβ plaques. However, it has also been suggested that the changes in the tau
protein and the resulting NFT tangle formation are stimulated by toxic concentrations of Aβ27.
4

Figure 1.3. Tau is a soluble protein23, but hyperphosphorylation causes the tau monomers to
bind together budding insoluble aggregates, which then affects normal neuronal function.
Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews] (Götz J and Ittner
LM, (7): 532-44), Copyright (2008).

1.1.2. Risk factors
There is now strong evidence of probable risk and protective factors for AD, dementia
and cognitive decline28, 29. AD has a number of contributing elements that lead to its composite
etiology, but age is the most important risk factor. Other factors that may lead to AD are brain
trauma, stroke, obesity, diabetes, hypertension, dyslipidemia, hyperhomocysteinemia, and metal
exposure30-32. Several genetic mutations are known to be associated with AD, such as mutations
in APP or presenilin1, 33-35. Presenilin is a component of the γ-secretase enzyme complex that
degrades APP into Aβ, leading to familial AD. Another genetic origin may be the isoforms of
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ApoE4 (the cholesterol transporter apolipoprotein) which, when homozygotic, raise the risk of
developing AD by about 15 times36.

1.1.3. Diagnosis
Scientists continue to look for diagnostic tools with suitable precision and accuracy to be
used while the patient is in the presymptomatic phase37, 38. Currently, conclusive diagnosis of AD
can only be made postpartum because of the inadequate understanding of its etiology39.
Therefore, there is an urgent need for an early biomarker of AD that could be used for
identifying presymptomatic patients for clinical trials, and, to allow treatment to be started at an
early phase of the disease40, 41.
Analysis of cerebrospinal fluid (CSF) levels of tau, phosphorylated tau or the ratio
between them, has been found to show neuronal degeneration associated with NFT
accumulation42-44. However, the strongest biomarkers for AD are brain imaging studies using
magnetic resonance imaging (MRI) or positron emission tomography (PET)45, 46. MRI can be
used to identify the characteristic pattern of degeneration in the temporal lobes. The
accumulation of Aβ can be detected through the use of radioactive tracers such as [18F]florbetapir47, 48 and Pittsburgh compound B (PiB)49-51 (Figure 1.4). Fluorodeoxyglucose- (FDG-)
PET imaging52,

53

can also be used to detect hypometabolism in the temporoparietal region,

which has been shown to distinguish successfully between AD and normal controls. In addition,
a complete medical history, mental status exam and blood tests are required to exclude other
origins of dementia-like symptoms.
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Figure 1.4. Structures of [18F]-florbetapir, [18F]-fluorodeoxyglucose and the PiB compound.

1.1.4. Current therapies
Since much of AD pathophysiology at the molecular level has yet to be understood fully,
there is no recognized cure for AD1. Only two classes of therapeutics (Figure 1.5) are presently
available for AD management54: the acetylcholinesterase (AChE) inhibitors (rivastigmine,
galantamine and donepezil) and one N-methyl D-aspartate (NMDA) receptor antagonist
(memantine)55-57. Unfortunately, these drugs only target the behavioral features of AD without
much enhancement of mental abilities or long-term quality of life. The cholinesterase inhibitors
are indicated for the treatment of patients in the mild to moderate stages of AD58. Memantine
works by increasing the concentration of glutamate, a neurotransmitter involved in learning and
memory, and is used for the treatment of moderate to severe AD59. There is also evidence that
memantine provides additional benefits in patients concurrently taking donepezil60, 61. Despite
the benefits these AD drugs offer, their use is limited, since they are effective for only
approximately one year and in only about half of the individuals to whom they are prescribed62.
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Figure 1.5. Structures of memantine, galantamine, rivastigmine and donepezil.

1.1.5. Agents under investigation
AD has been considered as a research priority because, although there are few existing
approved treatments, there is a need to develop more effective disease-modifying drugs.
Therefore, there is an ongoing enormous research effort targeting the development of effective
drugs. Many of the proposed disease-modifying AD treatments target the production and
clearance of Aβ in order to slow the disease progress and to improve behavioral and mental
symptoms63.
Table 1.1 shows some of the amyloid related therapeutics currently or previously tested
as treatment for AD. Amyloid related therapies64 presently under investigation include βsecretase inhibitors65, γ-secretase modulators66, α-secretase modulators67, Aβ aggregation
inhibitors68, metal chelators69 and immunotherapy70. β-secretase inhibitors aim to decrease the
concentration of Aβ1–42 peptides71. These agents target an important step of Aβ production (the
8

cleavage of APP) and, therefore, have some promising prospects. However, the active site of
secretases may be difficult to target because the molecules that bind to their active site tend not
to have properties that offer easy access through the blood-brain barrier (BBB)72. One such small
molecule drug, tarenflurbil73 (Table 1.1), which demonstrated good activity in Phase 2 clinical
trials, did not show considerable-enough benefits in the following larger controlled trials, a result
which was attributed to the challenge of BBB crossing.
Inhibiting the aggregation of Aβ is another mechanism of possible therapies being
investigated. One example of an aggregation inhibitor, tramiprosate74 (Table 1.1), did not
sufficiently inhibit Aβ aggregation, according to the results of clinical trials. Because Aβ may be
susceptible to unusual interaction with metal ions in the synaptic region, ionophores were
suggested as potential therapies for AD. Studies have shown the combined involvement of
copper and zinc in the precipitation of Aβ and plaques formation. Phase 2 studies of the metal
chelator, clioquinol75 (Table 1.1) have shown clinical benefit and reduced CSF Aβ
concentrations, but did not show significant benefits in Phase 3 trials76. There are a number of
factors that influence the processing, aggregation, and clearance of Aβ, posing potential
challenges. Therefore, many drugs continue to fail in clinical trials.
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Table 1.1. Amyloid related therapeutics, which are currently being tested or previously were
tested as treatments for AD.
Structure/Name

FDA status
Phase 2

O
OH

Target
Increases the expression of
α-secretase77

O
Acitretin

Failed in Phase 2

O N

γ-secretase inhibitor78

F

N

F

O
N
S
O
O

Cl

F
F

NH 2

Avagacestat

O
N
N

Phase 3

BACE inhibitor79

Phase 3

Inhibitor of RAGE, the
receptor
for
advanced
glycation end-products80

Phase 2

γ-secretase modulator81

N
NH 2

AZD3293

N

N

N

O

O
Cl

Azeliragon
Cl
Cl
OH

F

O
CHF 5074
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Cl

N

Failed in Phase 2

Metal
protein-attenuating
compound82

Failed in Phase 2

Prevents Aβ oligomers from
aggregating83

Failed in Phase 3

γ-secretase modulator73

Failed in Phase 2

γ-secretase modulator84

Failed in Phase 2

Synaptic vesicle
modulator85

Failed in Phase 2

BACE inhibitor79

I

OH
Clioquinol
OH
HO

OH

HO

OH
OH

ELND005

O
HO

F
Tarenflurbil

O
OH
Ibuprofen
O
NH 2

protein

N

O

Levetiracetam
S

O

H 2N

N

F

O

N

N
H

F
LY2886721

Phase 2

OH
N

N

PBT2

Cl

Cl
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Metal
protein-attenuating
compound86

Failed in Phase 3
OH

O

H
N

N

N
H

O
Semagacestat

O
NH 2

F

N

H
N

N
O

γ-secretase inhibitor87

BACE inhibitor88

Phase 2

Inhibits the expression of
BACE189

N
S O
O

F
Verubecestat
O

N

Phase 3

O
NH

O O
Thalidomide

O

Failed in Phase 2

Aggregation inhibitor84

H 2N

S
OH
O
Tramiprosate

A few of the new therapies have targeted tau phosphorylation or tau aggregation. Table
1.2 shows the tau-related therapeutics which are currently or previously tested as treatments for
AD. These include GSK-3β inhibitors and tau aggregation inhibitors (Table 1.2). Lithium’s
benefits of reducing tau pathology have been established in animal models of AD. Tideglusib90
is a thiadiazolinedione derivative and a non-ATP competitive GSK-3 inhibitor, and it became a
candidate in Phase IIb trials. The extended Phase II trial (60-day treatment) did not reveal
adverse effects but produced no significant clinical benefits. Another approach to reduce tau
pathology has been to directly inhibit tau aggregation; preliminary evidence suggests that
methylene blue (INN: methylthioninium chloride)91 (Table 1.2) may be particularly beneficial.
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Table 1.2. Tau related therapeutics which are currently or previously tested as treatment for AD.
Structure/Name
Lithium
N
S+
Cl-

N

FDA status
Phase 3
Failed in Phase 2

Target
GSK-3β inhibitor92
Tau
aggregation
93
inhibitor

Failed in Phase 2

Microtubule stabilizer94

Failed in Phase 2

GSK-3β inhibitor95

N

Methylthioninium chloride
O
OH
O

N

O

HO

S

O
Epothilone D

O
N
S

O

N

Tideglusib

O

O

Phase 1

Microtubule stabilizer96

Phase 3

Stabilized
form
of
methylthioninium
chloride, to improve the
drug's
absorption,
bioavailability,
and
tolerability97

O

O
O
HN
O

O
OH O

O
O

OH

O

O

O

Docetaxel
N
N

S

ClN+

TRx0237
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1.2. Protein kinases
Protein kinase-mediated cell signaling pathways play important roles in cell growth,
metabolism, differentiation, and apoptosis by catalyzing phosphorylation of about one third of
the proteome98. This is accomplished by transfer of the terminal γ-phosphate group of adenosine
triphosphate (ATP) to the hydroxyl acceptor group present on the side chains of the substrate
serine, threonine, or tyrosine (sometimes also histidine) residues99 (Scheme 1.1). Therefore, the
nucleophilic attack is performed by the hydroxyl oxygen of the substrate molecule.

N
H 2N
N

N

O

O

O
P

O
P

O
P

O
O
O
OH OH OH

H

O

R

OH

N HO

N
H

+

O

O
O
R
P
O

H 2N
N

+

N
N HO

O

O
OH

O
P

O
P

O
O
OH
OH

Scheme 1.1. Phosphoryl transfer reaction. One third of the proteome is phosphorylated by
different protein kinases.
Regulation of kinases has been implicated in a number of disease situations, including
cancer, diabetes and AD; this makes kinases a greatly targeted group of drug targets. To date,
numerous protein kinase experimental three-dimensional structures have been identified in both
active and inactive states, aiding general understanding of protein kinase mechanism100.
Protein kinases have a general well-preserved folding arrangement101, which involves two lobes:
a smaller N-terminal lobe (N-lobe) contains mostly β-sheets and a larger C-terminal lobe (Clobe) contains mostly α-helices. The two lobes form a hydrophobic cleft, which houses the ATP
molecule (Figure 1.6).
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A)

B)

Figure 1.6. A) The overall structural fold of the protein kinases. The N-lobe (shown in blue) is
mainly made of β-sheets, connecting loops and one functionally essential helix. The C-lobe
(shown in red) is mainly made of α-helices and connecting loops. B) The N-lobe forms a
hydrophobic pocket (hinge region), which accommodates the adenine ring of ATP.

The glycine-rich loop102, located in the N-lobe, acts as a lid on top of the ATP, assisting
the transfer of the γ-phosphate to the substrate (Figure 1.7). The activation segment103 (DFG
loop) contains the phosphorylation site that, upon phosphorylation, induces a conformational
movement on the loop that allows the substrate binding and converts the kinase from an inactive
form to a catalytically active form (Figure 1.7).
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Figure 1.7. Protein kinase structural features: hinge region (yellow loop), C-helix (pink),
glycine-rich loop (yellow beta-sheet) and activation loop (green loop).

The aspartate residue from the generally conserved Asp–Phe–Gly (DFG) motif forms
polar contacts with all three of the ATP phosphates, directly or through coordinating magnesium
atoms104, 105. The Mg2+ ions neutralize the triphosphates allowing the positioning of the ATP
molecule in the hydrophobic active site106 (Figure 1.8). The important lysine residue, which is
conserved in every known kinase, binds the α- and β-phosphates of the ATP molecule and forms
an important polar contact with a conserved glutamic acid residue107 (Figure 1.9). There are two
major possibilities to inhibit protein kinases: ATP competitive inhibition and non-ATP
competitive inhibition108. The non-ATP competitive inhibitors, for example, substrate
competitive inhibitors, usually participate in a weak binding interaction with the enzyme109. NonATP competitive inhibitors do not compete with the intracellular ATP, which presents in high
concentration, and therefore have a pharmacological benefit.
16

Figure 1.8. The Mg ions neutralize the triphosphates permitting the placing of the ATP molecule
in the hydrophobic pocket.

Figure 1.9. The ionic interaction between the conserved Lys72 and Glu91 residue.
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1.3. Protein kinases as AD targets
It has become clear that AD is a cross-linked disease with numerous pathological events.
A faulty mechanism demonstrated in AD is protein phosphorylation regulated by protein kinases.
Studies have shown that several kinases initiate the excess formation of plaques and of
neurofibrillary tangles leading to Alzheimer’s-like dementias110 (Figure 1.10). Protein kinases
are emerging therapeutic targets for AD, particularly after the failure of several agents that target
the Aβ cascade to demonstrate therapeutic usefulness in clinical testing. One therapeutic goal is
to inhibit the protein kinases that mediate the phosphorylation of amino acid residues mostly
found to be phosphorylated in Alzheimer’s brain111. However, protein kinases’ involvement in
many vital signaling pathways has the possibility to cause many off-target effects112. Thus,
protein kinase inhibitors appropriate for AD treatment have to strike a balance between the
different pathways by moderate inhibition and favorable pharmacokinetics.
Out of the seven known kinase families, some members of five families (CMGC, CaMK,
AGC, STE, and TKL) have been studied in the context of AD113. Several kinases are involved in
the four primary domains relevant to the neurodegeneration found in AD including APP
processing, tau hyperphosphorylation, neuroinflammation, and neurotoxicity114. These kinases
include cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 5 (CDK5), glycogen
synthase kinase-3 (GSK-3α and GSK-3β), protein kinase C-epsilon (PKC-ε) and the protein
kinase RNA-like endoplasmic reticulum kinase (PERK)115. In the following sections we will
describe the role of each kinase in the pathogenesis of AD.

18

Figure 1.10. Protein kinases have several actions in the pathology of AD116. They are involved
in the mRNA splicing of tau protein, phosphorylation of tau protein at multiple sites, and APP
cleavage by the β- and γ-secretases to form Aβ. Reprinted from: J Exp Clin Med, 4(3), Liu HC,
Leu SJ, Chuang DM. Roles of Glycogen Synthase Kinase-3 in Alzheimer’s Disease: From
Pathology to Treatment Target, 135-139, Copyright (2012), with permission from Elsevier.

1.3.1. CDK1 as a kinase target for AD
CDK1 acts in the cell cycle by modulating the centrosome cycle and mitotic onset. CDK1
interacts with multiple cyclins to support G1 phase progress and its transition to S phase117. It
phosphorylates several cellular proteins including APC, AMPH and Bcl-xL98. CDK1 is regulated
by phosphorylation at Thr 14 or Tyr 15 to inactivate the enzyme, and phosphorylation at Thr 161
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to activate it118. Also CDK1 binding to cyclin-B is an essential step to relocate the kinase
complexes into the nucleus119. The capability of a CDK1 inhibitor to stop Aβ cytotoxicity
suggests that CDK1 is a prospective target of AD120. Studies have established the important role
of the CDK1 enzyme in Aβ cytotoxicity through its phosphorylation of Aβ121. The location of
the gene that expresses CDK1 within the same locus on chromosome 10 that is associated with
increased Aβ levels is evidence of this role122. The CDK1 gene also contains a single nucleotide
polymorphism, which affects the amino acid residue 59; an isoform contains an arginine residue
and another contains a glycine residue at position 59123. The affected N-terminal region of CDK1
contains the cyclin binding site and the amino acid changes could therefore impact the kinase
activity. The levels of both CDK1 protein and cyclin B1 are elevated in AD brains124. The Aβ
peptide binds to cyclin B1 and increases the activity of the CDK1/cyclin B1 complex125. Since
there is a clear connection between the amyloid and tau theories in etiology of AD, the ability of
Aβ to directly increase the activity of CDK1 may also contribute to the phosphorylation
abnormality features of AD126, 127. Aβ toxicity involves other members of the CDK family, as
cyclin B1 is able to activate kinases other than CDK1128. The ability of CDK1 inhibitors to
prevent Aβ cytotoxicity suggests that CDK1 is a potential target of AD therapeutic agents
(Figures 1.11 and 1.12). Several chemical classes inhibit CDK1 including oxoindoles,
pyrazolo[3,4-b]pyridines, indazole analogs, indolin-2-ones, pyridine derivatives, purine
derivatives, pyrimidine derivatives and flavopiridol derivatives129.
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Figure 1.11. A 2D interaction model of the CDK1 ligand. The docking pose of the inhibitor
shows hydrogen bonds and π-π stacking with the amino acid residues of CDK1.
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Figure 1.12. A CDK1 inhibitor bound into the CDK1 ATP binding site. The binding site of
CDK1 (homology model) is shown as a surface surrounding the CDK1 ligand (shown as sticks
with white carbon atoms). The secondary structure is colored by residue.

1.3.2. CDK5 as a kinase target for AD
Substantial progress has been made regarding understanding the contribution of CDK5 to
the pathophysiology of AD130, 131. Studies using animal models of AD largely confirmed that
CDK5 deregulation contributes to neuronal loss in the disease. Indeed, studies revealed that
selective inhibition of CDK5–p25 (the truncated activator, Figure 1.14) reduces the Aβ-induced
neuronal loss in cortical neurons132, 133. CDK5 is implicated not only in tau hyperphosphorylation
but also in regulating the generation of Aβ134. CDK5 activation increases Aβ production and
accumulation in the cell body and neurites, while CDK5 inhibition attenuates Aβ production in
transgenic mice overexpressing p25134, 135.
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Further studies revealed that CDK5 phosphorylates STAT3 and enhances its
transcriptional activity, resulting in elevated transcription of BACE1, thereby increasing Aβ
generation120, 136. In accordance with the identification of CDK5 as a tau kinase, knockdown of
CDK5 decreases tau phosphorylation and NFT formation in triple-transgenic Alzheimer’s
mice137,

138

. Furthermore, Aβ-induced activation of CDK5 is suggested to mediate local

phosphorylation of tau, leading to the dissociation of tau from microtubules139, 140. CDK5 also
facilitates tau phosphorylation by inhibiting phosphatase enzymes137. In addition, CDK5mediated phosphorylation of CRMP2141, another microtubule binding protein that is
hyperphosphorylated in patients with AD, is particularly resistant to dephosphorylation. These
findings together indicate that CDK5 may also enhance phosphorylation of microtubule binding
proteins in AD by interfering with their dephosphorylation.

Figure 1.14. The structure of CDK5 (dark green) in complex with its activator, p25 (light green),
(PDB code 1UNG142).
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Several crystal structures of CDK5 have been released (Table 1.3) in complex with
inhibitors illuminating the basic structural features of the enzyme and the ligand-enzyme
interaction profile (Figures 1.15-1.16).

Table 1.3. Examples of the released crystal structures of CDK5 and their cognate ligands.
PDB Code

Ligand
N

Resolution (Å)

H
N
OH

N

1UNG142

2.30
H
N
O
NH

N
HO

1UNH

143, 144

2.35

NH
HO
N
H

1UNL144

N

N

N

N

2.20

Cl
O
HN

3O0G145

O
N+

S
N

NH 2

24

O-

1.95

Figure 1.15. The CDK5 ligand binds in the ATP pocket of the enzyme (PDB code 1UNG142).
The protein is colored using residue color scheme.

Figure 1.16. The 2D interaction model of the CDK5 ligand (PDB code 1UNG142).
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1.3.3. GSK-3 as a kinase target for AD
GSK-3 was originally discovered as a participant in glycogen metabolism, but also plays
an important role in cell proliferation, apoptosis and immune response pathways146. GSK-3 is
known to play key roles in the regulation of several cellular events and also in the
phosphorylation of several protein substrates147. Phosphorylation at serine 21 (for the GSK-3α
isoform) or at serine residues 9 and 389 (for the GSK-3β isoform) inhibits GSK-3 activity
whereas phosphorylation at tyrosine 279 (for GSK-3α isoform) and at tyrosine 216 (for GSK-3β
isoform) increases GSK-3 activity148. GSK-3 phosphorylation can be catalyzed by several
protein kinases including cAMP-dependent protein kinase A (PKA) and protein kinase C
(PKC)148. GSK-3 is also considered as a central switch in receiving signals for growth factors,
insulin and amino acids149, 150. GSK-3 is known for its role in the determination of cell-fate
during embryogenesis, phosphorylation of the WNT signaling-pathway and inhibition of geneexpression by the degradation of beta-catenin151, 152. It also regulates axon-growth during brain
development, neurogenesis and neuronal polarization153,

154

. There is much evidence that

demonstrates the role of GSK-3 in the pathophysiology of AD155. Studies show increased levels
of GSK-3α and -3β in the frontal cortex of AD brains and accumulation of the same in the
somatodendrites at all stages of neurodegeneration156, 157. The activation of GSK-3β as an early
event is usually preceding and/or accompanying the NFTs’ formation158.
Tau phosphorylation by GSK-3 occurs at 42 sites, 29 of which are found in the
phosphorylated state in AD brains137, 159. Overexpression of GSK-3 in transgenic mice induces
tau hyperphosphorylation and consequently neurodegeneration, and a GSK-3 inhibitor may
reverse both processes160. Moreover, GSK-3 overexpression in cell lines causes apoptotic cell
death, suggesting that tau phosphorylation by GSK-3 could be toxic161. The central role of GSK26

3 in AD, specifically tau pathogenesis, was clearly established by exposing cultured rat
hippocampal neurons to Aβ peptide, increasing GSK-3 level, tau phosphorylation and neuronal
cell death162.
In animal models, the increase of GSK-3 activity is involved in tau phosphorylation,
memory impairment, inflammatory response, increased production of Aβ and reduced
acetylcholine synthesis (a cholinergic deficit is observed in AD)163, 164. In AD patients, GSK-3
co-localizes with NFTs and the active form of GSK-3 (phosphorylated at tyrosine 216) increases
in the frontal cortex of AD brains115. Due to the increase in GSK-3 activity in AD brains and its
involvement in the acceleration of tau pathology, GSK-3 seems to be a promising therapeutic
target against tauopathies like AD.
The structures of GSK-3β co-crystallized with several inhibitors have been solved by Xray crystallography. These structures encourage for the design of both novel and selective GSK-3
inhibitors. However, the majority of the known GSK-3 inhibitors are ATP competitive and target
the ATP binding site of GSK-3165. Several GSK-3 inhibitors can be extracted from the Protein
Data Bank (PDB) (Table 1.4, Figures 1.17 and 1.18).

27

Table 1.4. Examples of the released crystal structures of GSK-3β and their cognate ligands.
PDB Code

Ligand

Resolution (Å)
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O
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O

O
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Figure 1.17. The GSK-3β inhibitor in complex with the enzyme (PDB code 4ACG180)
31

Figure 1.18. The 2D interaction model of the GSK-3β inhibitor (PDB code 4ACG180). The
cognate ligand shows several hydrogen bonds, π-π stacking and hydrophobic contacts.

1.3.4. PKC-ε as a kinase target for AD
The term protein kinase C (PKC)181 refers to a serine/threonine family of phosphorylating
enzymes that have significant roles in numerous cellular functions by transducing signals
involved in short-term activities (ion fluxes, neurotransmitter release), mid-term processes
(receptor modulation), as well as long-term processes (cell proliferation, synaptic remodeling
and gene expression)182. According to sequence homology and sensitivity to activators, about 10
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isoforms (determined by nine different genes) have been described, and may be grouped into 3
distinct classes: (1) calcium-dependent or classical; (2) calcium-independent or novel nPKCs;
and finally (3) atypical aPKCs183. The general construction of the different PKCs includes
preserved domains (C1–C4) separated by variable sequences (V1–V5). C1 and C2 represent the
regulatory portion of each enzyme with which the activators bind, while C3 and C4 form the
catalytic region required for both the substrate binding and the kinase activity183, 184. There is a
high degree of shared homology among the kinases particularly at the catalytic domain.
The C1 domain bears one (in atypical) or two (in conventional and novel) cysteine-rich
regions, located close to the amino-terminal region, that characterize the docking sites for
phosphatidylserine (PS) and the known physiological activator diacylglycerol (DAG) as well as
for the phorbol esters, which activate all the different PKCs, with the exception of the atypical
isoforms (that are activated by phosphatidylinositol-3,4,5-trisphosphate)185.
The C2 region contains the Ca2+ binding-site and is present in both the conventional and
the novel isoenzymes186, 187. However, the nPKCs are not responsive to Ca2+ because of the
absence in the C2-like domain of amino acids residues essential for the Ca2+ binding: recruitment
to membrane is dependent on a C1 region with higher affinity for phospholipids (in comparison
with cPKCs)188. Lastly, C3 contains the ATP binding portion (Figure 1. 19), while C4 comprises
the substrate docking sequence189.
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Figure 1.19. Cartoon representation of the 3D model of the kinase domain of PKC-ε.

It has been shown that PKC-ε reduces Aβ levels in vitro and in vivo190, 191. PKC-ε acts on
the stimulation of Aβ degradation in the brains of PKC-ε transgenic mice that express
amyloidogenic variants of human APP190,

191

. The activation of the α-secretase-mediated

cleavage of APP may be conducted directly by PKC isozymes α and ε or indirectly through PKC
activation of ERK1/2, or both190, 191.
On the other hand, Aβ can inactivate PKC: Aβ contains a putative PKC pseudosubstrate
site (Aβ28–30), which is critical for Aβ–PKC direct interaction. Aβ1–40, at high concentrations,
also reduced PKC-mediated phosphorylation of several soluble brain proteins in a liposome
system. Addition of Aβ1–40 peptides to cultured B103 cells reduced the activated form of PKCε192, 193. This also suppressed phorbol ester-mediated membrane translocation of PKC-ε without
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changing its expression level, demonstrating that activation of intracellular PKC-ε is reduced by
treatment with Aβ peptides.
Decreased PKC-ε activation leads to the following194:
(1)

Deactivation of HuD, an mRNA binding protein important in the stability and genetic

expression of various mRNAs that play a role in neuronal plasticity of the CNS.
(2)

Decreased mRNA stability of NEP (the major physiological Aβ-peptide degrading

enzyme in the brain), allowing Aβ accumulation and disease progression.
It was observed in AD transgenic mice that activation of PKC-ε195 could prevent
synaptotoxic Aβ-oligomer elevation, synaptic damage, cognitive insufficiencies, and amyloid
plaque growth. Additionally, the treatment of AD mice and an aged rat model with bryostatin, a
selective PKC-ε activator (Figure 1.20), can dramatically reduce levels of Aβ, regenerate
neurotrophic activity and synapses, and improve cognitive function190,

196, 197

. Furthermore, a

severe AD patient who was confirmed to have a known genetic variant of PSEN1, showed
promising benefits with bryostatin treatment of the kind not previously shown with any other
treatment(s)198. Thus, isoform-specific PKC activators are highly desirable as potential antiAlzheimer’s drugs.
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Figure 1.20. The chemical structure of bryostatin (left) and its proposed binding pose with PKCε domain C1B.

1.3.5. PERK as a kinase target for AD
PERK, also known by names such as PEK or EIF2AK3, is predominantly activated in the
endoplasmic reticulum (ER) by means of misfolded protein-accumulation199-201. This
phenomenon is called ER stress202. The synthesis of new polypeptides is blocked by PERK
through the phosphorylation of eIF2α, thereby hindering the entry of the nascent polypeptides
into the lumen of the ER. This enhances the time necessary for the ER to refold and dispose of
the terminally misfolded proteins that are important elements for the cell’s unfolded protein
response (UPR), thereby restoring the ER homeostasis202.
Normally, UPR should be ended after resolving the ER stress203. However, in case of AD,
the neuronal cells in the temporal cortex and the hippocampus continue to produce misfolded
proteins, which keeps activating the UPR, preventing its programmed turn off35, 204. The role of
PERK has gained much importance in recent years based on its implications in pathologies like
diabetes, ischemia, and cancer205. PERK is an ER transmembrane-protein with its N-terminal
region located inside the lumen of the ER while the C-terminal is cytosolic206. The N-terminal
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region interacts with other proteins and is important for regulation, association and binding to the
immunoglobulin binding protein (BiP), an ER chaperone207, 208. The C-terminal region includes
the kinase domain and the autophosphorylation sites207. The specific trigger for PERK activation
remains unclear, with self-dimerization being considered to be critical. PERK is bound to BiP in
its inactive state with misfolded proteins competing with PERK in the ER lumen for BiP
binding207, 208. The dissociation of BiP from PERK is known to be caused by the accumulation of
misfolded proteins, thereby leading to dimerization.
The stimulation of UPR signaling is known to induce tau phosphorylation209. The
phosphorylation of the UPR stress-sensor PERK and its downstream substrate eIF2α are
observed in AD brains209. Also, activation of the related kinase PKR correlates to the ER stresslevels in AD brains. In vitro studies suggested an interesting ER stress connection between tau
hyperphosphorylation and Aβ-mediated neurotoxicity210. Interestingly, neurons with active
PERK are known to express active GSK-3β in the affected neurons of the AD brain211. The risk
factors associated with the development of sporadic tauopathies include genetic variants related
to single nucleotide polymorphisms in the PERK gene (Figure 1.21).
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Figure 1.21. The eIF2α kinase (PERK) becomes activated in response to accumulation of
amyloid and tau aggregates212. Persistent eIF2α phosphorylation through aberrant activation of
this kinase in AD causes the inhibition of overall translation, while it triggers gene-specific
translation of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), which is responsible
for the generation of Aβ. PERK also activates the activating transcription factor 4 (ATF-4),
which in turn suppresses the cAMP response element-binding protein (CREB). The CREB
proteins in neurons are involved in the formation of long-term memories. Figure reproduced with
permission from Masuo Ohno (2014), Roles of eIF2α kinases in the pathogenesis of Alzheimer’s
disease. Front. Mol. Neurosci. 7: 22. doi: 10.3389/fnmol.2014.00022.
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Recently, it has been shown that the UPR is activated in AD brain, with detection of increased levels of BiP and phosphorylated PERK in the temporal cortex and the hippocampus.
Screening for PERK inhibitors led to the identification of the compound GSK2606414213 with
IC50 of 3.2 nM and it was co-crystallized with the PERK kinase do-main (PDB ID, 4G31213).
Other reported PERK inhibitors that have been co-crystallized with the PERK kinase domain are
shown in Table 1.5 and Figures 1.22 and 1.23. Identification of the role of the UPR/PERK/eIF2α
signaling pathway in the pathophysiology of neurodegenerative diseases led to the emergence of
PERK as a novel therapeutic target for AD.

Table 1.5. Examples of the released crystal structures of PERK and their cognate ligands.
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GSK2606414213 was found to be neuroprotective during testing in mice. Mice have been
cured from Creutzfeldt–Jakob disease upon treatment with GSK2606414. Because the
mechanism of neuronal death is the same in both diseases, Creutzfeldt–Jakob disease and AD,
the neuroprotective ability of GSK2606414 is a strong motivation to search for new PERK
inhibitors.

Figure 1.22. The binding pose of PERK–GSK2606414213,

215

. The receptor site is shown as

surface and the protein secondary structure is colored using residue color scheme. The amino
acid residues involved in interaction with the ligand are shown as lines.
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Figure 1.23. PERK–GSK2606414213 (1-[5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5yl]-2,3-dihydro-1H-indol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone)

interaction

profile213.

This schematic diagram (not to scale) shows that the trifluoromethyl group forms hydrophobic
interactions with several hydrophobic amino residues (green spheres); the carbonyl group forms
a hydrogen bond with a structural water molecule; the purine ring forms a π-π interaction with
the aromatic ring of F943; and the amino group and the pyrimidine nitrogen form hydrogen
bonds with Q888 and C890, respectively.
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1.4. Summary
The demanding need for new disease-modifying drugs of AD requires development of
new treatment strategies and finding alternative drug targets. Several kinases are strongly
involved in AD progression through tau phosphorylation and the amyloid cascade. One
therapeutic goal is to inhibit kinases that mediate the phosphorylation of amino acid residues
found to be hyperphosphorylated in Alzheimer’s brain. These kinases include CDK1, CDK5 and
GSK-3 (α and β). AD intervention can also be accomplished through reduction of Aβ levels,
which is possible through development of PKC-ε activators. PKC-ε activators could help
reinstate NEP levels and activity in the AD brain, leading to a substantial decrease of toxic Aβ
levels, and therefore re-establish synaptogenesis and cognitive function. Recently, ER stress has
been agreed upon as an important factor in neurodegenerative diseases including AD. Increasing
the number of unfolded proteins in the ER causes release of ER chaperones from the stresssensing domain of PERK. PERK phosphorylates eIF2α, transforming eIF2α to an inhibitor of
the ribosome translation initiation complex, and consequently shutting down protein production,
leading to neuronal cell death. We ultimately aim to develop new AD drugs by targeting some of
the kinases significantly involved in the pathophysiology of AD. In Chapter 2, we describe the
construction of 3D models of CDK1, GSK-3α and PKC-ε. In Chapter 3, we present structural
analysis and thermodynamic calculations of CDK1, CDK5, GSK-3 and PERK. In Chapter 4, we
show the study of protein-ligand interactions using molecular dynamics simulations. Finally,
Chapter 5 will demonstrate three virtual screening protocols to find new inhibitors/ activators of
these protein kinases.
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CHAPTER 2. GENERATION OF 3D MODELS OF THE KINASE DOMAINS OF CDK1,
GSK-3α, AND PKC-ε

Manal A. Nael and Robert J. Doerksen
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2.1. Introduction
The standard homology modeling procedure216 consists of seven main tasks including;
recognition of template protein(s) which is/are highly homologous to the query sequence,
sequence alignment, backbone generation, loop modeling, side chain construction, structure
optimization and validation. We used Prime module of the Schrödinger suite217-219 to construct
and refine the 3D models. The secondary structure and the relative solvent accessibility of the
query sequence were predicted by using SSPro and PSIPRED modules220,

221

. We then used

3DLigandSite to define the amino acid residues in the ATP binding site222. The information from
structurally similar protein was used predict the active sites.

2.1.1. Homology modeling methodology
The amino acid sequence of human CDK1 was obtained from The Universal Protein
Resource (UniProt) (http://www.uniprot.org)223,

224

. To define the most homologous protein

structure to the query sequence all the experimentally released protein structures in the PDB
repository225 (http://www.rcsb.org) were searched using the Prime [Basic Local Alignment
Search Tool226 (BLAST)] homology search tool. To ensure complete search, we used the PSIBLAST227 (Position-Specific Iterative BLAST) as the search tool, the non-redundant database
from the National Center for Biotechnology Information228 (NCBI NR) as the search database,
and the BLOcks SUbstitution Matrix229 (BLOSUM62, that is built using sequences with no more
than 62% similarity) as the similarity matrix. All homologous experimental protein structures
were retrieved and ranked based on their similarity to the query sequence.
We used the search option for globally conserved residues to identify the protein family
to which the query sequence belongs. We ran the HMMER program230 on the Pfam database231
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to generate a Hidden Markov Model (HMM) from a multiple sequence alignment and identify
the query family based on the Expectation value (E-value) and provide information about which
residues are conserved in the consensus sequence.
The secondary structure and the relative solvent accessibility of the query sequence
were predicted by using the SSPro and PSIPRED programs220, 221. We aligned the template and
query sequences using the ClustalW tool232. This was done through a position-specific
substitutional matrix (PSSM) for the query sequence that is derived from the PSI-BLAST result
and is used to match the template sequence217,

218

. We constructed a composite secondary

structure for the query sequence from multiple predictions in order to minimize the possible
inaccuracy of relying on a single secondary structure. The composite secondary structure
prediction (SSP) was aligned to the secondary structure assignment (SSA) of the template. Based
on the globally conserved residues that were defined in the previous step, we made necessary
alignment edits using the Single Template Alignment (STA) program to generate an accurate
alignment between proteins with medium to high sequence identity (20-90%)233. We used the
composite/chimera model builder of Prime to use multiple templates to construct 10 models for
each target sequence. We retained all rotamers for conserved residues, and we optimized the side
chains by minimizing all residues that were not derived from the templates. We allowed the
option of omitting the structural discontinuities if there is a gap in the template (insertion) of
more than 20 amino acids. We used the loop refinement option to correct atomic charges and
bond orders, and to fix disparities that existed between the sequence and the structure. The
geometry of the final 3D model was then optimized by running extensive energy minimization
using the OPLS2005 force field234 and with the Variable-Dielectric Surface Generalized Born
model235 (VSGB), as a solvation model. The root mean square (RMS) gradient for convergence
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was set to 0.001 kcal/mol/Å. The protein structure quality was checked using the Procheck
software236. We used the 3DLigandSite to predict the possible ligand cavity and the amino acid
residues involved in ATP binding. 3DLigandSite222 is a web server which succeeded in
predicting the ligand binding pockets of several proteins in the eighth round of the Critical
Assessment of techniques for protein Structure Prediction222 (CASP-8). The information from
similar structures was used to predict these sites. Similar protein structures were aligned to the
model to allow for placing the ligands in the 3D model. Other structural motifs were predicted
based on the protein family information.

2.1.2. Results and discussion
CDK1 is found in two isoforms123: 1 and 2. Isoform 2 differs from isoform 1 in that it
is missing the residues from 107-163. Isoform 2 is known to exist in breast cancer tissues and is
reported to accumulate following the G1 and S phases of the cell cycle. Isoform 1 is the
canonical sequence and it is composed of 297 amino acids:

MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQ
DVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNL
LIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKP
LFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKM
LIYDPAKRISGKMALNHPYFNDLDNQIKKM
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The PSI-BLAST search for sequence homologs retrieved all similar experimental
structures and we selected three templates (1UNL143, CDK5; 1GZ8237, CDK2 and 1OB3238, P.
falciparum CDK5) based on percent identity to our target sequence (Table 2.1).

Table 2.1. Template structures used in modeling CDK1.
Template (PDB Code)

Identities

Positives

Gaps

Pfam

1GZ8237

64%

78%

3%

27/25

1OB3238

60%

73%

1%

31/25

1UNL143

56%

72%

1%

28/25

The three templates were aligned to the query sequence (Figure 2.1). Required
alignment edits were made based on the information retrieved from the Pfam of globally
conserved residues. SSPro was used in this step to assign the secondary structures of the template
and target proteins. CDK-1, as expected, contains a protein kinase domain with very high
expectation value (E-value = 1.1e-78). We generated HMMER/Pfam consensus sequence (see
new-0_pfam in Figure 2.1) using the globally conserved residues and the identified protein
family of the query sequence. Different symbols are used in Pfam alignment to refer to the
different matching states such as capital letters are used for highly conserved positions,
lowercase letters for residues that match the HMM, and + for residues that are conserved
according to HMM. We used the coloring scheme option to show residue matching as in Figure
2.1, taking into consideration that template residues are only colored if they match the query,
while query residues are only colored if they match residues in one or more templates. The
matching residues are colored according to residue property: gray if not matching, dark green for
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amino acid residues Ala, Phe, Ile, Leu, Met, Val and Tyr, blue for Lys and Arg, light blue for
Asn and Gln, red for Asp and Glu, yellow for Cys, purple for Gly, cyan for His, orange for Pro,
pink for Ser and Thr, and green for Trp. The alignment of the query sequence and CDK5 (PDB
code 1UNL) is shown in Figure 2.2. We constructed 10 models for CDK1 and we found the
loops that were modeled as flexible to be far from the ligand binding site (Figure 2.3).

Figure 2.1. Sequence alignment and secondary structure assignment of the query (-new-0) and
template structures. The globally conserved amino acid residues (new-0-pfam), and the template
proteins [1GZ8 (human CDK2), IUNL (human CDK5), and 1OB3 (P. falciparum CDK5)] are
colored based on matching. SSPro was used to assign the secondary structures.
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Figure 2.2. Alignment of the CDK1 sequence (Query) with CDK5 (PDB ID: 1UNL as
Template) showing 1: predicted secondary structures, 2: query sequence, 3: temple sequence, 4:
template known secondary structure, 5: template predicted secondary structure. Dark brown
blocks show insertions relative to the template. Orange blocks show deletions relative to the
template. Red squares around particular template sequences are for known catalytic sites.
Secondary structure information is represented using G for 3-turn helix (310 helix), I for 5-turn
helix (π helix), T for hydrogen bonded turn, B for residue in isolated β-bridge, and S for bend.
Identical residues are highlighted with a grey background.
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Figure 2.3. Cartoon representation of a CDK1 model using yellow for the α-helices, red for the
β-sheets and green for the loops. The loops that are modeled to be flexible are shown in boxes,
and are found far from the ligand binding site. CDK1 is bilobial with the N-lobe mostly
composed of β-sheets and the C lobe mostly α-helices. The binding pocket is at the intersection
of the two lobes.

We calculated the hydrophobic and hydrophilic properties of the models (Figure 2.4)
using the Protein Patch Analyzer239 to build protein surface patches to predict the protein sites
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that are highly prone to promote aggregations. This application aids in understanding protein
properties and making decision in mutation studies. The hydrophobic/hydrophilic patches were
determined using a van der Waals solvent accessible interaction surface. To calculate the
interaction surface, a lattice is considered and a 0-potential contour is prepared of the van der
Waals potential of a probe water oxygen atom with each residue. The positions at which the van
der Waals energy of the oxygen atom probe is positive are those at the interior of the 0-potential
surface and the exterior of the 0-potential contains the negative interaction energy. This is
calculated as follow:
𝑣 𝑥 =

&

𝐴& 𝑥 − 𝑥&

()*

− 𝐵& 𝑥 − 𝑥&

(,

where v(x) is the van der Waals potential, Ai and Bi are the OPLSA-AA240 van der Waals
parameters with a water oxygen used as a probe. The interaction surface is significant at the
points which are in close contact to the water oxygen, and therefore this calculation is similar to
calculating the solvent accessible surface of a molecule. We calculated three classes of patches
by considering the electrostatic and hydrophobic potential calculations. Thus we were able to
define the negative and positive hydrophobic patches on the protein. The positive and negative
patches are associated with positive and negative electrostatic potentials, respectively. The
hydrophobic potential241 is calculated using the following equation:
2 12

𝐸./0 =
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where Exyz is the potential, fi is the contribution for atom i and g(di)242 is the Fermi-type distance
function:
𝑔 𝑑& =
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with a proximity distance (dcutoff) of 2.5 Å and α = 1.5.
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Figure 2.4. The aggregation-prone regions (APRs) in the CDK1 model. The CDK1 model is
shown using cartoon representation with yellow for β-sheets and red for α-helices. The number
of hydrophobic patches (hyd) is one and that patch is colored using a green surface. We noted
two negative patches colored red and eight positive patches colored blue.

The aggregation-prone regions (APRs) in proteins are characterized by high surface
exposure and strong interaction potential, ARPs become surface exposed upon conformational
transition to facilitate intermolecular interaction. The interaction potential is calculated using the
previous equations. The surface exposure is calculated by rolling a protein probe with a 5.0-Å
radius over the target protein. The properties associated with each patch are calculated (Table
2.2). Because different residues have different roles in the known forms of protein aggregation,
we checked all residues that are represented in the patches. Positions exposed to arginine
residues are prone to deamidation or glycosylation. Tyrosine residues which are surface exposed
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can form covalent species. The highly surface-exposed arginine residues that we found in CDK1
are Arg50, Arg59, Arg75, Arg122, Arg123, Arg151, Arg158 and Arg180. There is no amino
acid residue we can consider as a candidate for glycosylation in close proximity to these arginine
residues, while Gln98 can undergo deamidation. Lys296 was also found to be surface exposed.

Table 2.2. Properties of the protein patches.
ID

Type

Area

%ASA

Max E

Avg E

N

O

1

hyd

135.11

2.50

0.31

0.13

2

2

−

485.10

8.99

89.20

52.56

23

3

−

57.63

1.07

70.91

46.00

4

+

134.24

2.49

145.42

82.69

5

5

+

77.80

1.44

109.59

68.06

2

6

+

72.34

1.34

117.85

79.60

2

7

+

67.00

1.24

124.63

74.47

2

8

+

63.56

1.18

167.39

86.15

1

9

+

62.28

1.15

125.60

74.15

2

10

+

52.52

0.97

116.48

74.33

1

11

+

52.21

0.97

113.52

77.47

2

1

1

hyd for hydrophobic, − for negative and + for positive patch types. Area: Water-accessible
surface area in square Ångstroms; % ASA: Percentage of patch to total protein surface area;
Max, Avg: Maximum/average patch potential values (kcal/mol); N, S, O: Number of highly
accessible nitrogen, sulphur and oxygen atoms; and W: Number of highly accessible tryptophan
residues.
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The following amino acid residues are associated with the prospective patches. The
hydrophobic patch implicates Gln98, Tyr99 and Met100. The negative patch (2) is associated
with Leu37, Glu38, Ser39, Glu40, Glu41, Glu42, Val44, Ser46, and Ser74. Negative patch 3
contains Gly97, Met100, Asp101, and Ser102. Positive patch 4 consists of Arg123, Arg180 and
Ser182. Patch 5 is associated with Arg122, patch 6 with Arg61, Pro61 and Ly143, patch 7 with
Gln98, Met100 and Lys296, patch 8 with Leu37 and Arg75. Patch 9 contains Ser46 and Arg50.
Patch 10 associated with Arg151 and patch 11 with Arg158.
We verified the quality of the models to consider more refinement for any distortion.
The quality of a protein structure is estimated by comparing all residue values with that reported
proteins in the PDB. The model was checked for allowed and disallowed dihedral angles, main
chain parameters, residue properties, bond lengths, planarity and distorted geometry. We used
the Ramachandran plot243 to check the dihedral angles. Generally, glycine residues are plotted as
triangles; proline residues as squares and all other amino acid residues are plotted as circles.
All amino acids were found in the allowed regions of the Ramachandran plot (Figure
2.5), 94.2% of the amino acids are in the core regions and 5.7% in the generously allowed ones.
Chi1-chi2 angles, which describe the dihedral angles of the side chains, are in the acceptable
limits for each amino acid. The main parameters including peptide bond planarity, bad nonbonded interactions, Calpha tetrahedral distortion, main-chain hydrogen bond energy and overall
G-factor, showed comparable results to well-refined structures at resolution of 2.5 Å.
The side chain parameters including standard deviation of the chi-1 gauche minus
torsion angles, standard deviation of the chi-1 trans torsion angles, standard deviation of the chi1 gauche plus torsion angles, pooled standard deviation of all chi-1 torsion angles, standard
deviation of the chi-2 trans torsion angles, are also comparable to well-refined structures at
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resolution of 2.5 Å. Residue properties show a maximum deviation of 2.0 Å with no bad
contacts. In general, the 3D models were found to be suitable to be used in our further
calculations.

Figure 2.5. The Ramachandran plot of the CDK1 model. Glycine amino acid residues are plotted
as triangles, proline residues are shown as squares and all other amino acid residues are plotted
as circles.
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In order to start the structure based drug design process we need to predict the ligand
binding sites. We used 3DLigandSite222 to determine the amino acid residues included in the
ligand pocket as well as the ATP binding site. The information from structurally similar
experimental protein structures was used to guide predicting these sites. Similar protein
structures were aligned to the model to allow for placing the ligands in the 3D model (Figures
2.6 and 2.7). Table 2.3 shows the protein (PDB) files that were used in the prediction of the
ligand binding pockets.

Figure 2.6. Similar protein structures (PDB codes: 1AQ1244, 1J1C245, 2B9J246, 2B9H246, 2B9I246,
1HCK247, 1B38248, 1B39248, 1FQ1249, 1QMZ250, 1GY3250, 2CCI251, 2CJM252, 1R3C253, 3BLQ166,
1PYX167, 1LP4254, 3GC0255, 1JST256, and 1UA2257) aligned with CDK1 model. The protein
structures are shown as cartoon with distinct color for each protein.
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Figure 2.7. Prediction of the ligand binding sites in the CDK1 model. All ligands are extracted
from other known experimentally defined proteins. Ligands are shown as sticks, metal ions as
green spheres. The amino acid residues which are surrounding the ligand binding pockets are
shown in blue and the other parts of the protein are shown in grey cartoon.

Table 2.3. The ligands and PDB files used to predict the active site of CDK1 model.
Ligand
STU
ADP
MG

Count
1
4
18

AMP
ATP

1
13

Source structures
1AQ1
1J1C, 2B9J, 2B9I, 2B9H
1HCK,
1B39,
1B38,
1GY3,
2CCI,
2CJM,
1J1C,
1PYX,
2B9J,
1LP4
3GC0
1HCK,
1B39,
1B38,
1QMZ,
1FIN,
1GY3,
2CJM, 1UA2, 3BLQ
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1FQ1,
1R3C,
2B9I,

1QMZ,
3BLQ,
2B9H,

1FQ1,
2CCI,

2CCH,
1JST,

Table 2.4 illustrates the amino acid residues that are associated with the ligand binding
sites. Figure 2.8 shows the plausible ligand-binding pocket of CDK1 model. Others structural
motifs were predicted based on the protein family information.

Table 2.4. The amino acid residues included in the active site of CDK1 model.
Residue
10
12
13
14
15
16
18
31
33
64
80
81
82
83
86
132
133
135
146

Amino acid
ILE
GLU
GLY
THR
TYR
GLY
VAL
ALA
LYS
VAL
PHE
GLU
PHE
LEU
ASP
GLN
ASN
LEU
ASP

Contacts*
19
18
20
20
17
17
19
19
19
13
18
19
19
19
14
15
21
12
22

Average distance*
0.17
0.22
0.00
0.04
0.05
0.11
0.01
0.03
0.01
0.46
0.20
0.00
0.00
0.00
0.32
0.08
0.28
0.38
0.11

*Contacts to a residue are defined as the number of ligands (in the cluster of similar protein
structures) that contact this specific residue. Average distance is the average of the distances
between the residue and all ligands in the cluster.
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Figure 2.8. The amino acid residues included in the active site of the CDK1 model. Left: The
predicted ligand binding site of CDK1; amino acid residues surrounding the binding pocket are
shown as cyan sticks, and the two most possible positions of Mg2+ ions based on binding site
similarity with known protein structures are shown as green spheres. Right: surface
representation of the binding pocket, in which AMP is shown as sticks.

Other sites are predicted from the protein family information including:
•

CDK/cyclin interface (Figure 2.9, green cartoon spots): L37, E42, G43, V44, S46, I49,
R50, I52, S53, K56, E57, M71, V117, H120, S121, R122, R123, R151, A152, F153,
I155, P156, Y160, T161, A273, S277, G278, K279

•

Polypeptide substrate binding site (Figure 2.9, cyan spots): R50, K88, D128, K130,
L149, T161, E163, V164, V165, T166, W168, G206 and D207

•

Activation loop (A-loop) (Figure 2.9, pink spots): A145, D146, F147, G148, L149,
A150, R151, A152, F153, G154, I155, P156, I157, R158, V159, Y160, T161, H162,
E163, V164, V165, T166, L167 and W168
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•

ATP binding site (Figure 2.9, red spots): I10, G11, E12, G13, V18, A31, K33, V64, F80,
E81, F82, L83, D86, K89, Q132, N133, L135 and D146

•

Active site (Figure 8): I10, G11, E12, G13, V18, A31, K33, R50, V64, F80, E81, F82,
L83, D86, K88, K89, D128, K130, Q132, N133, L135, D146, L149, T161, E163, V164,
V165, T166, W168, G206 and D207

Figure 2.9. Different structural motifs of the CDK1 model: CDK/Cyclin interface is shown in
green, the polypeptide binding site in cyan, the activation loop in pink and the ATP binding site
in red. The protein is shown as white cartoon except for the described motifs.
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2.2. Construction of 3D model of GSK-3α
GSK-3α is a protein kinase, which phosphorylates glycogen synthase, beta-catenin, APC
and AXIN1 and subsequently inactivates them258. Because it inhibits the activity of glycogen
synthase by phosphorylation, GSK-3α helps in the insulin control of glycogen synthesis259. It is
reported that GSK-3α regulates the processing and generation of the APP and APP-derived
amyloid plaques that are found in AD259. GSK-3α phosphorylates the anti-apoptotic protein
MCL1 and shows a prominent role in cell apoptosis. GSK-3α is activated when phosphorylated
at Tyr279, and inhibited by phosphorylation at Ser21260.

2.2.1. Homology modeling method
The amino acid sequence of human GSK-3α was downloaded from the UniProt
database. We used the standard homology modeling procedure to construct the 3D models as we
did in case of the generation of the CDK1. We validated the homology models using the protein
quality option of Bioluminate261-263 and by Procheck software236. Ligand binding pockets and
structural motifs were predicted by 3DLigandSite222 and protein family characteristics.

2.2.2. Results and discussion
GSK-3α is found in a single isoform and consists of 483 amino acids and the kinase
domain represents the amino acids from 119 to 403. The sequence of GSK-3α is shown below as
obtained from the UniProt224 database and the kinase domain is highlighted in yellow.
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MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSS
GGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFG
VVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEY
VPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCD
FGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLV
EIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEAC
AHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPT
SSDWQSTDATPTLTNSS

In this study, we are interested in constructing the 3D model of the sequence representing
the kinase domain. We used the protein family information to find out the part of the sequence
with the highest E-value for protein kinase family, and the amino acids highlighted in yellow
were found to have an E-value of 2.38e-65. Because of the high sequence identity, the
experimentally solved crystal structure of GSK-3β was used as a template in the homology
modeling experiment. We modeled GSK-3α using GSK-3β (PDB ID: 4ACC180, Figure 2.10),
which have a percent identity of 91% to GSK-3α and a resolution of 2.21 Å. While in a previous
study in our lab264 it was modeled using 1Q41167 (80% identity and 2.1 Å resolution). We built
10 models; in these models the variable loops were found to be located far from the expected
ligand-binding pocket (Figure 2.11). We checked the models for quality as in case of CDK1
model. The selected model was found to be acceptable to be used in subsequent calculations. All
amino acids were found in the allowed regions of the Ramachandran plot (Figure 2.12), 92% of
the amino acids are in the core regions and 8% in the generously allowed ones. Chi1-chi2 angles,
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the main and the side chain parameters are comparable to well-refined structures at resolution of
2.5 Å. Residue properties show a maximum deviation of 2.3 Å with no bad contacts.

Figure 2.10. Alignment of the sequences of GSK-3α (Query) and GSK-3β (PDB ID: 4ACC as
Template) showing 1: predicted secondary structures, 2: query sequence, 3: template sequence,
4: template known secondary structure, 5: template predicted secondary structure. Brown blocks
for insertions relative to template. Orange blocks for deletions relative to template. Red squares
around particular template sequences for known catalytic sites. Secondary structure information
is represented by G for 3-turn helix (310 helix), T for hydrogen bonded turn, B for residue in
isolated β-bridge, and S for bend. Identical residues are highlighted with a grey background.
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Figure 2.11. Cartoon representation of the GSK-3α model colored yellow for the α helices, red
for the β sheets and green for the loops. The loops that are modeled to be flexible are shown in
boxes, and are found far from the ligand binding sites (indicated by cyan arrow). GSK-3α is
bilobial with N lobe mostly composed of β-sheets and the C lobe as α-helices. The binding
pocket is at the intersection of the two lobes.
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Figure 2.12. Ramachandran plot of the GSK-3α model. Glycine amino acid residues are plotted
as triangles, proline residues are shown as squares and all other amino acid residues are plotted
as circles.
We identified the hydrophobic and hydrophilic properties of the models (Figure 2.13) by
applying the Protein Patch Analyzer utilizing a van der Waals solvent accessible interaction
surface. The surface of negative and positive potential is calculated using oxygen atom probe.
The properties associated with each patch are calculated (Table 2.5). Because different residues
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have different roles in the known forms of protein aggregation, we checked all residues that are
represented in the patches (Table 2.6).

Figure 2.13. The aggregation-prone regions (APRs) in the GSK-3α model. GSK-3α is shown as
cartoon representation colored yellow for the β-sheets and red for the α-helices. The
hydrophobic patches are colored green, negative patches are colored red and positive patches are
colored blue.
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Table 2.5. Properties of the protein patches.
Id
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Type
hyd
hyd
hyd
hyd
hyd
hyd
hyd
hyd
hyd
hyd
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
−
+
+
+
+
+
+
+
+
+
+
+
+
+

Area
470.86
373.84
354.78
171.26
120.36
102.57
98.85
58.67
52.74
50.71
468.47
315.55
223.06
185.65
174.82
134.44
125.21
107.44
99.17
88.20
87.79
74.94
74.15
67.16
65.52
64.60
63.18
52.39
214.20
191.97
157.20
152.59
130.02
126.43
109.44
101.64
100.69
93.84
91.38
85.64
80.22

% ASA
3.65
2.90
2.75
1.33
0.93
0.79
0.77
0.45
0.41
0.39
3.63
2.44
1.73
1.44
1.35
1.04
0.97
0.83
0.77
0.68
0.68
0.58
0.57
0.52
0.51
0.50
0.49
0.41
1.66
1.49
1.22
1.18
1.01
0.98
0.85
0.79
0.78
0.73
0.71
0.66
0.62

Max
0.19
0.19
0.21
0.20
0.20
0.21
0.17
0.20
0.16
0.14
30.16
29.15
26.55
30.73
28.42
28.98
28.19
27.79
16.24
28.00
30.81
25.59
27.71
13.48
16.50
19.41
13.74
23.86
39.33
42.17
41.37
36.88
33.73
36.70
29.59
35.52
37.11
36.38
34.92
36.92
37.70
68

Avg E
0.13
0.13
0.13
0.12
0.13
0.13
0.13
0.13
0.11
0.09
13.25
12.68
12.82
13.25
10.91
12.75
12.80
11.77
8.65
14.02
13.63
9.48
15.88
6.98
8.96
8.83
7.91
11.07
13.60
17.90
16.44
12.81
12.17
13.62
9.75
12.47
14.79
15.12
15.23
12.46
14.24

N
1
1
2

O

S

1
1
1
9
3
4
2
2
1
3
1

3

2
2
2

1

1
1
1
3
5
1
4
2
3

1
1
2

1
2
2
2
2

1
1

1

1

42
+
43
+
44
+
45
+
46
+
47
+
48
+
49
+
50
+
51
+
52
+
53
+
54
+
hyd for hydrophobic,

76.00
0.59
38.26
16.89
1
74.32
0.58
37.69
13.70
1
74.14
0.57
34.99
12.02
3
1
73.39
0.57
35.53
13.63
1
70.40
0.55
38.83
15.57
1
64.78
0.50
39.15
15.72
62.78
0.49
37.78
16.12
1
60.72
0.47
33.87
11.63
2
59.67
0.46
37.85
17.36
1
58.91
0.46
35.42
13.94
2
57.20
0.44
35.58
14.93
1
56.23
0.44
37.32
17.55
1
52.85
0.41
34.26
14.30
1
− for negative and + for positive patch types. Area: Water-accessible

surface area in square Ångstroms; % ASA: Percentage of patch to total protein surface area;
Max, Avg: Maximum/average patch potential values (kcal/mol); N, S, O: Number of highly
accessible nitrogen, sulphur and oxygen atoms; and W: Number of highly accessible tryptophan
residues.

Table 2.6. Residues associated with the respective patches.
ID
1

Type
hyd

2

hyd

3

hyd

4

hyd

5
6
7
8
9

hyd
hyd
hyd
hyd
hyd

Ala139
Leu101
Val105
Glu235
Lys216
Glu70
Leu33
Tyr1
Ala28
Lys30
Val55
Phe60
Ile162
Ala115
Phe38
Lys248

Ala94
Leu26
Val87
Phe174
Lys211
Phe61
Arg58
Tyr16
Cys144
Leu133
Val80
Leu71
Val159
Cys280

Residues
Glu82
Phe91
Leu96
Pro136
Tyr102
Tyr106
Phe236
Phe238
Pro239
Val208
Ile29
Ile4
Val14
Val27
Tyr59
Tyr72
Asp145
Phe12
Leu77
Met46
Tyr79
Tyr62
Tyr161
Leu277
Arg112

Pro245
69

His90
Pro81
Tyr79
Ile215
Val212
Lys31
Val6

Lys104
Pro99

Phe146
Thr83

Ile7
Val15

Ile241
Tyr233
Leu20
Val76

10
11

hyd
−

12

−

13

−

14

−

15

−

16
17
18
19

−
−
−
−

20
21

−
−

22

−

23
24
25
26
27
28
29

−
−
−
−
−
−
+

30
31
32
33
34
35

+
+
+
+
+
+

36
37
38

+
+
+

Lys128
Ala176
Glu267
Gln225
Ser272
Ala139
Leu26
Thr23
Asp205
Pro200
Val212
Ala281
Lys104
Asp50
Arg56
Asp69
Asp69
Glu156
Phe250
Pro256
Glu235
Asp126
Ser148
Ala88
Thr92
Glu22
Gly121
Asp35
Glu82
Phe12
Asp3
Phe38
Gln4
His90
Ile162
Leu26
Cys52
Lys251
Ile173
Ser164
Glu66
Cys52
Arg154

Pro200
Ala260
Glu278
Arg227
Ser275
Asp135
Pro136
Val105
Asp209
Pro203
Tyr166
Glu257
Pro256
His51
Tyr116
Glu70
Glu66
Gly155
Ile259
Arg53
Phe236
Asp145

Pro203
Asp178
Leu274
Arg273
Thr180
Asp137
Pro81
Val140
Glu213
Gln199

Tyr166
Glu171
Asp158
Ser263
Thr269
Glu25
Gln109
Val80
Glu204
Arg165

Tyr167
Glu224
Pro231
Ser264
Trp246
Glu78
Arg58
Tyr79
Ile201
Ser206

Glu278
Ser283
Lys48

Phe284

Phe285

His282

Leu49

Leu57

Arg47

Lys67
Glu70
Lys150
Lys248
Ser252
Asn232
Lys128

Lys68
Lys67
Gln151
Lys251
Thr247
Pro231
Lys30

Leu33
Lys68
Arg154
Leu197
Thr254
Thr234
Asn131

Glu194
Tyr85

Gly198

Pro129

Pro200

His118
Phe38
Pro81
Gly10
Arg19
Phe60
Arg41
Lys93
Lys150
Arg19
Glu78
Arg253
Lys128
Tyr161
Gly65
His51

Gln120
Lys36
Arg86
Gly13
Thr2
Lys39
Ag47
Arg86
Arg125
Arg24
Lys142
Ser252
Gln130

Gln151
Gln34
Val87
Asn9

Ser119
Arg37
Tyr79
Ser11

Leu43

Aspn9

Gln34

Arg89
Arg41

Tyr85
Ser148

Val159

Arg56
Thr254
Gln210

Arg58
Arg165

Arg168

Lys31
Arg112

Ser63
Tyr108

Ser64

Tyr16
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Glu228
Pro270
Ser271
Tyr179
Lys142
Thr138
Lys216
Val208

Ser64
Val153
Pro255
Val249
Gln130
Arg89

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Arg223
Ile45
Lys251
Ala243
Asp3
Arg165
Glu70
Lys95
Ala21
His244
Phe38
Arg237
Arg227
Phe284
Lys68
Lys67

Lys48
Leu96
Lys242
Lys
Tyr166
Lys36
Thr92
Glu22
Lys248
Arg37

Gln151
Thr97

Gln44

Pro81

Gln17

Leu20
Pro245

Thr23

Tyr1

Ile100

Lys104

Leu101

Pro99

Leu71

Leu33

The patch analyzer did not show any surface exposed tryptophan residues. There are
several arginine residues are found to be highly surface exposed including Arg112, Arg227,
Arg165, Arg47, Arg56, Arg154, Arg253, Arg89, Arg37, Arg86, Arg19, Arg41, Arg24 and
Arg223. The residue Asn9 is expected to be a candidate for glycosylation, while Gln151 and
Gln120 are considered sites for deamination. Several lysine residues are also found to be highly
surface exposed including Lys104, Lys31, Lys248, Lys48, Lys67, Lys68, Lys36, Lys39, Lys93,
Lys242, Lys5, Lys95 and Lys237. There is no exposed tyrosine residues or other residues with
exposed oxygen atoms.
The plausible location and the amino acid residues surrounding the ligand-binding pocket
and ATP binding site were identified using 3DLigandSite. We used the information from the
structurally similar proteins. The protein structures were aligned using the 3D model as the
reference of frame to place the ligands and predict the ligand-binding pocket (Figures 2.14 and
2.15). A 23 protein structures (Table 2.7) were found to have similar binding sites, and the
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coordinates of their ligands were transferred to the 3D model. The positions of Mg2+ in the
binding site were calculated (Figure 2.16 and Table 2.8).

Figure 2.14. Similar protein structures (PDB codes: 1Q3D166, 1J1C245, 1Q8Y265, 2B9J246,
2B9H246, 2B9F246, 1DS5266, 1PYX167, 1DAY267, 1DAW267, 1LP4267, 1Q97265, 2CCI251, 1QMZ250,
1GY3250, 1FQ1249, 1GOL268, 2JD5269 and 1JNK270) aligned with the GSK-3α model. The protein
structures are shown as cartoon with distinct color for each protein.
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Figure 2.15. A cartoon representation of the 3D model of GSK-3α showing the ligand binding
sites. All ligands are extracted from other known experimentally defined proteins. Ligands are
shown as sticks and metal ions as green spheres. The amino acid residues surrounding the ligand
binding pockets are shown in blue and the other parts of the protein is shown as grey cartoon.
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Table 2.7. The ligands and PDB files aligned with GSK-3α model to predict the active site.
Ligand
STU
ADP

Count

Source structures

1
6

1Q3D
1J1C, 1Q8Y, 2B9J, 2B9H, 2B9F

MG

23

AMP
ATP

1
9

1DS5, 1PYX, 1DAY, 1DAW, 1LP4, 1Q97, 1J1C, 2CCI,
1QMZ, 1GY3, 1Q8Y, 1FQ1, 2B9J, 2B9H, 2B9F, 1GOL,
2JD5, 1JNK
1DS5
2CCH, 1Q97, 2CCI, 1QMZ, 1GY3, 1FIN, 1JST, 1FQ1,
1GOL

Figure 2.16. The predicted active site of the GSK-3α model. Amino acid residues surrounding
the binding pocket are shown as cyan sticks, and the possible positions of Mg2+ ions based on
binding site similarity with know protein structures are shown as green spheres.
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Table 2.8. The amino acid residues included in the active site of GSK-3α model.
Residue
7
12
15
28
30
55
78
79
80
83
130
131
133
144
145

Amino acid
ILE
PHE
VAL
ALA
LYS
VAL
GLU
TYR
VAL
THR
GLN
ASN
LEU
CYS
ASP

Contacts
17
17
16
16
15
14
17
17
17
15
16
28
17
13
33

Average distance
0.17
0.00
0.25
0.02
0.20
0.37
0.00
0.00
0.00
0.21
0.09
0.29
0.20
0.55
0.23

Other binding sites and important motifs were predicted from alignment with known
proteins using 3DLigandSite, and Conserved Domain Database search. These domains include:
•

Activation loop (A-loop) (Figure 2.18: green): C144, D145, F146, G147, S148, A149,
K150, Q151, L152, V153, R154, E156, P157, N158, V159, S160, Y161, I162, C163,
S164, R165, Y166

•

ATP binding site (Figure 2.18: yellow): I7, G8, N9, G10, V15, A28, K30, V55, L77,
E78, Y79, V80, T83, K128, Q130, N131, L133, D145

•

Polypeptide substrate binding site (Figure 2.18: red): R41, Y85, D126, K128, S148,
V159, Y161, I162, C163, S164, Y166, G204

•

Axin site (Figure 2.18: orange): I173, V208, D209, L211, V212, I215, K216, F236,
K237, F238, P239, Q240, I241
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•

Active site (Figure 2.18: blue): I7, G8, N9, G10, S11, V15, A28, K30, R41, V55, L77,
E78, Y79, V80, T83, Y85, R86, D126, K128, Q130, N131, L133, D145, S148, V159,
Y161, I162, C163, S164, Y166, G204

•

Dimer interface (Figure 2.18: wheat): S11, F12, P157, N158, V159, S160, Y161, I162,
C163, S164, R165, I173, F174, D205, S206, G207, V208, D209, L211, V212, K216,
F236, K237, F238, P239

Figure 2.17. GSK-3α motifs: Activation loop is shown in green, ATP binding site in yellow,
polypeptide binding site in red, axin site in orange, active site in blue and dimer interface in
wheat. The protein is shown as white cartoon except for the described motifs.
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2.3. Construction of 3D model of PKC-ε
PKC-ε is a serine/threonine-protein kinase which is calcium-independent and
phospholipid-dependent271. PKC-ε was found to have essential roles in the regulation of several
cellular processes including multiple functions associated with cytoskeletal proteins (cell cycle,
cell adhesion, motility and migration). PKC-ε play important functions in ion channel regulation
and neuron growth, which is found to be important in AD271.

2.3.1. Homology modeling method
The amino acid sequence of human PKC-ε was downloaded from the UniProt database.
We used the typical homology modeling procedure to construct the 3D models similar to what
we did in case of CDK1 model. We validated the homology models using the protein quality
option of Bioluminate and by Procheck software. 3DLigandSite and protein family features were
used to predict ligand binding pockets and structural motifs.

2.3.2. Results and discussion
PKC-ε contains 737 amino acids and is found in one isoform. The following is the
amino acid sequence of PKC-ε as downloaded from the Uniprot database. We highlighted in
green the amino acids residues from 169 to 220, which represent the first zinc finger domain
(C1A, Phorbol-ester/DAG-type 1). The residues from 242 to 292 represent the second zinc finger
domain (C1B, Phorbol-ester/DAG-type 2) and are highlighted in cyan. The residues from 408 to
668 characterize the kinase domain and are highlighted in yellow.
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10
20
30
40
MVVFNGLLKI
KICEAVSLKP
TAWSLRHAVG
PRPQTFLLDP
60
70
80
90
IGQTATKQKT
NSPAWHDEFV
TDVCNGRKIE
LAVFHDAPIG
110
120
130
140
QFEELLQNGS
RHFEDWIDLE
PEGRVYVIID
LSGSSGEAPK
160
170
180
190
MRPRKRQGAV
RRRVHQVNGH
KFMATYLRQP
TYCSHCRDFI
210
220
230
240
CQVCTCVVHK
RCHELIITKC
AGLKKQETPD
QVGSQRFSVN
260
270
280
290
KVPTFCDHCG
SLLWGLLRQG
LQCKVCKMNV
HRRCETNVAP
310
320
330
340
KVLADLGVTP
DKITNSGQRR
KKLIAGAESP
QPASGSSPSE
360
370
380
390
PCDQEIKELE
NNIRKALSFD
NRGEEHRAAS
SPDGQLMSPG
410
420
430
440
KRLGLDEFNF
IKVLGKGSFG
KVMLAELKGK
DEVYAVKVLK
460
470
480
490
DCTMTEKRIL
ALARKHPYLT
QLYCCFQTKD
RLFFVMEYVN
510
520
530
540
SRKFDEPRSR
FYAAEVTSAL
MFLHQHGVIY
RDLKLDNILL
560
570
580
590
FGMCKEGILN
GVTTTTFCGT
PDYIAPEILQ
ELEYGPSVDW
610
620
630
640
MAGQPPFEAD
NEDDLFESIL
HDDVLYPVWL
SKEAVSILKA
660
670
680
690
GCVASQNGED
AIKQHPFFKE
IDWVLLEQKK
IKPPFKPRIK
710
720
730
DFTREEPVLT LVDEAIVKQI NQEEFKGFSY FGEDLMP

50
YIALNVDDSR
100
YDDFVANCTI
150
DNEERVFRER
200
WGVIGKQGYQ
250
MPHKFGIHNY
300
NCGVDARGIA
350
EDRSKSAPTS
400
ENGEVRQGQA
450
KDVILQDDDV
500
GGDLMFQIQR
550
DAEGHCKLAD
600
WALGVLMYEM
650
FMTKNPHKRL
700
TKRDVNNFDQ

In this case, we are interested in modeling the zinc finger domain type 2 (C1B) because
of the studies have confirmed its role in AD if activated. We decided to model both the kinase
and C1B domains to ensure a complete picture of the enzyme. We used the specific protein
family information to select the amino acid sequence for modeling. In case of the kinase domain
the E-value was 3.8e-68. We selected protein kinase C, alpha type (PDB ID: 3IW4, Figure 2.18)
as a template to model the target sequence because they share more than 65% homology identity.
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We then constructed 10 models, and the variable loop was found to be far from the expected
ligand binding area (Figure 2.19).
The model was validated using Bioluminate and Procheck softwares. All amino acids
were found in the permitted regions of the Ramachandran plot (Figure 2.20), 95.4% of the amino
acids are in the main regions and 4.6% in the generously allowed ones. Chi1-chi2 angles, the
main and the side chain parameters are analogous to well-refined structures at resolution of 2.5
Å. Residue properties show a maximum aberration of 2.1 Å with no bad contacts.
We applied the Protein Patch Analyzer to search for the hydrophobic and hydrophilic
possessions of the models (Figure 2.21). This was done employing the van der Waals solvent
accessible interaction surface calculations. The surface of negative and positive potential was
calculated using oxygen atom probe. The patch analyzer did not show any surface exposed
tryptophan residues. There is no exposed tyrosine residues or other residues with exposed
oxygen atoms.
The expected ligand binding pockets and the amino acid residues surrounding them were
detected by 3DLigandSite. To do so, we used the information from the structurally similar
proteins. The protein structures were aligned using the 3D model as the reference of frame to
place the ligands and predict the ligand binding pockets (Figures 2.22 and 2.23). A 26 protein
structures (Table 2.8) were found to have similar binding sites, and the coordinates of their
ligands were transmitted to the 3D model. The positions of Mg2+ in the binding site were
calculated (Figure 2.24 and Table 2.9).
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Figure 2.18. Sequence alignment and secondary structure assignment of the query (-new-0) and
template structures. The globally conserved amino acid residues (new-0-pfam), and the template
protein (3IW4272, human PKC-α) are colored based on matching. SSPro was used to assign the
secondary structures.

Figure 2.19. Cartoon representation of the kinase domain of PKC-ε models colored yellow for
α-helices, red for β-sheets and green for loops. The loops that are modeled to be flexible are
shown in boxes, and are found to be far from the ligand binding sites (indicated by cyan arrow).
Kinase domain of PKC-ε is bilobial with the N lobe consists mostly of β-sheets and the C lobe
consists mostly of α-helices. The binding pocket is at the intersection of the two lobes.
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Figure 2.20. Ramachandran plot of PKC-ε model.

Figure 2.21. The aggregation-prone regions (APRs) in the PKC-ε model. The kinase domain of
PKC-ε is shown as cartoon. The β-sheets are colored yellow and α-helices are colored red. The
hydrophobic patches are colored green, the negative patches are colored red and the positive
patches are colored blue.
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Figure 2.22. `similar protein structures (PDB codes: 3C50273, 3C4Z273, 3C4W273, 3C51273,
3C4X273, 2ACX274, 1RDQ275, 1Q24276, 1L3R277, 2V55278, 1MQ4279, 1OL5280, 1JKK281) aligned
with the kinase domain model of PKC-ε. The protein structures are shown as cartoon with
distinct color for each protein.
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Figure 2.23. A cartoon representation of the PKC-ε model showing the ligand binding sites. All
ligands are extracted from other known experimentally defined proteins. Ligands are shown as
sticks and metal ions as green spheres. The amino acid residues surrounding the ligand binding
pockets are shown as blue spots and the other parts of the protein are shown as grey cartoon.

Table 2.9. The ligands and PDB files used to predict the active site of PKC-ε model.
Ligand
STU
MG
ADP
ATP

Count
2
18
9
10

Source structures
1STC, 1OKY
3C50, 3C4Z, 3C4W, 3C51, 3C4X, 2ACX, 1RDQ, 1Q24, 1L3R,
2V55, 1MQ4, 1OL5, 1JKK
3C50, 3C4Z, 3C51, 2QUR, 1RDQ, 1JBP, 1L3R, 1MQ4, 1OL5
2BIY, 3HRF, 3HRC, 3C4W 3C4X 1H1W, 3FJQ, 1RDQ, 1Q24,
1ATP
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Figure 2.24. Predicted active site of the kinase domain of PKC-ε model. Amino acid residues
surrounding the binding pocket are shown as grey sticks, and the possible positions of Mg2+ ions
based on binding site similarity with known protein structures are shown as green spheres.

Table 2.10. The amino acid residues included in the active site of PKC-ε.
Residue
7
8
9
10
11
12
13
15
28
30
63
79
80
81
82
129
130
132
143

Amino acid
LEU
GLY
LYS
GLY
SER
PHE
GLY
VAL
ALA
LYS
THR
MET
GLU
TYR
VAL
ASP
ASN
LEU
ASP

Contacts
14
21
22
22
28
19
19
21
21
20
13
11
21
10
21
12
15
21
27
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Average distance
0.34
0.19
0.00
0.03
0.02
0.02
0.17
0.00
0.08
0.00
0.42
0.57
0.05
0.48
0.19
0.27
0.41
0.27
0.11

Other sites and domains include:
•

Activation loop (Figure 28, red spots): A142, D143, F144, G145, M146, C147, K148,
E149, G150, I151, L152, N153, G154, V155, T156, T157, T158, T159, F160, C161,
G162, T163, P164, D165

•

ATP binding site (Figure 25, orange spots): L7, G8, K9, G10, S11, V15, A28, K30,
T63, E80, Y81, V82, D86, D125, K127, D129, N130, L132, A142, D143

•

Polypeptide substrate binding site (Figure 25, orange spots): S11, D86, M88, D125,
K127, D129, M148, F160, C161, G162, T163, P164, D165, E192, P198, E201

Figure 2.25. PKC-ε structural motifs: its activation loop is shown in red, with its ATP binding
site in orange and polypeptide binding site in green. The protein is shown as white cartoon
except for the designated motifs.

In case of the C1B domain the E-value was 1.2-16 for Phorbol-ester/DAG-type 2. We used
the first solved structure of human PKC C1 domain, theta type (PDB ID: 2ENZ282, Figure 2.26)
as a template to model the target sequence because they share more than 67% homology identity.
We then constructed 20 models because the percentage of the disordered structure was about
22% (Figure 2.27). The models were validated using Bioluminate and Procheck softwares. All
85

amino acids were found in the acceptable sections of the Ramachandran plot (Figure 2.28), 98%
of the amino acids are in the core areas and 2% in the generously allowed ones. Chi1-chi2
angles, the main and the side chain parameters are similar to well-refined structures at resolution
of 2.5 Å. Residue properties demonstrated a maximum deviation of 1.2 Å with no bad contacts.
We utilized the Protein Patch Analyzer to find the hydrophobic and hydrophilic properties of the
models (Figure 2.29).
The expected ligand binding pockets and the amino acid residues surrounding them were
detected by 3DLigandSite and fpocket283, 284 (geometry-based cavity detection algorithm). We
used the knowledge from the structurally related proteins. The protein structures were aligned
using the 3D model as the reference of structure to place the ligands and predict the ligand
binding pockets (Figure 2.30). Nineteen structures (Table 2.10) were found to have similar
binding sites, and the coordinates of their ligands were transmitted to the 3D model. The
positions of ZN2+ in the binding site were calculated (Figure 2.30 and Table 2.11). We checked
the orientation of proteins in membranes (OPM) database285,
domain attaches to the plasma membrane.
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286

to find out how could C1B

Figure 2.26. Alignment of PKC-ε C1B domain (query) and the second c1 domain from human2
protein kinase c theta (PDB ID: 2ENZ as template) sequences, showing 1: predicted secondary
structures; 2: query sequence; 3: template sequence; 4: template known secondary structure, 5:
template predicted secondary structure. Brown blocks are for insertions relative to the template.
Orange blocks are for deletions relative to the template. Secondary structure information is
represented using: T for hydrogen bonded turn; B for residue in isolated β-bridge; and S for
bend. Identical residues are highlighted with a grey background.

Figure 2.27. Cartoon representation of the aligned C1B domain models colored yellow for the
α-helices, red for the β-sheets and green for loops. The amino acid residues are shown as lines
with unique color for each model.
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Figure 2.28. The Ramachandran plot of the C1B domain of PKC-ε model.

Figure 2.29. The aggregation-prone regions (APRs) in the C1B domain of PKC-ε. The C1B
domain is shown as cartoon colored yellow for the β-sheets and red for the α-helices. The
hydrophobic patches are colored as green surface, negative patches are colored in red and
positive patches are colored in blue.
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Figure 2.30. A cartoon representation of the C1B domain model of PKC-ε showing the Zinc
binding site. Zinc ions as violet spheres. The protein is shown as grey cartoon. The expected
membrane orientation is shown, with the upper cell membrane shown as red spheres and the
lower as blue sphere.

Table 2.11. The ligand and PDB files used to predict the Zinc binding site.
Heterogen
ZN

Count
258

Source structures
3CXL, 3BJI, 2YUU, 2ENZ, 2ENN,
2ELI, 2E73, 2DB6, 1Y8F, 1XA6,
1R79, 1PTR, 1PTQ, 2VRW, 1TBO,
1TBN, 2ROW, 1X4J, 1RFH

Other sites and domains include:
•

Zinc binding sites (Figure 31, green spots): H2, C15, C18, C32, C35, H40, C43, C51

•

Putative DAG/PE binding site (Figure 31, red spots): Y9, P12, T13, L22, W23, G24,
L25, L26, R27, Q28

•

Putative RAS interaction site (Figure 2.31, yellow spots): P12, F14
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Figure 2.31. PKC-ε C1B motifs: Zinc binding sites are shown in green, putative DAG/PE
binding site in red, putative RAS interaction site in yellow. The protein is shown as white
cartoon except for the described motifs.

2.4. Summary
For the protein kinases, whose experimental structures have not been solved yet, we
followed the standard procedures of comparative modeling to construct their expected 3D
models. We used Prime module of the Schrödinger suite to create and refine the 3D models. We
used Bioluminate and Procheck softwares for the assessment of the models. All amino acids
were found to be in the allowed or the generously allowed regions of the Ramachandran plot.
Chi1-chi2 angles, the main and the side chain parameters were comparable to well-refined
structures at a resolution of 2.5 Å. Residue properties showed a maximum deviation of 2.1 Å
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with no bad contacts. We applied the Protein Patch Analyzer to check for the hydrophobic and
hydrophilic properties of the generated models.

In addition, we used knowledge from

structurally similar proteins to define the amino acid residues in the ATP binding site as well as
in other important sites and motifs.
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CHAPTER 3. STRUCTURAL ANALYSIS AND THERMODYNAMIC CALCULATIONS OF
THE ACTIVE SITES OF CDK1, CDK5, GSK-3 AND PERK

Manal A. Nael and Robert J. Doerksen
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3.1. Introduction
We performed structural analysis of the protein kinases involved in AD. We studied the
different motifs’ structures such as ATP binding site, ligand binding pocket, and activation loop.
We also identified the conserved structural water molecules of CDK5, GSK3β and PERK (have
many experimentally solved kinase domains). In addition, we performed thermodynamic and
water mapping calculations for the active sites to estimate the effects of ligand’s functional
groups modifications on its binding affinity.

3.2. Methods
3.2.1. Searching for conserved motifs
We explored for the common structural motifs and domains of GSK-3β, CDK5 and
PERK using the Conserved Domain Database287 by applying PSI-BLAST variant227, RPSBLAST287, to scan against pre-calculated position-specific scoring matrices (PSSMs)288. To
ensure high confidence associations between the query sequence and conserved domains, an
expectation value of 0.01 was used.

3.2.2. Identifying experimentally conserved water molecules
To identify the consensus water molecules in GSK-3β, CDK5 and PERK, we retrieved all
the X-ray crystal structures with high resolution (≤ 3.0 Å), which are similar to the query
structures. The structures are then split into their individual chains and superimposed with the
query structure. We selected the PDB files (4AU8289 for CDK5, 1QI4290 for GSK-3β and
4G31213 for PERK) as the search inquiries. Only structures of at least 95% sequence identity with
the query structures were considered. Mobility is used for quality refinement of water in all
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crystal structures291. Mobility is defined by the crystallographic temperature factor (B-factor) and
the atom occupancy. Water molecules are discarded if their oxygen atoms showed mobility
values >2.0 Å for each structure. Crystal structures after refinement were aligned to the query
structures using the backbone as the reference291. Then, hierarchical clustering was performed on
the 3D Cartesian coordinates of all the water molecules. Euclidean distance metric, the complete
linkage algorithm, was used in clustering to ensure that at most, only one water molecule from
each superimposed structure is present in the cluster291. Then, the degree of water conservation
was calculated as the number of water molecules in a cluster divided by the total number of
aligned protein structures. Clusters having a degree of conservation of 0.47 were considered as
conserved.

3.2.3. Water mapping
We used SZMAP292 to analyze the thermodynamic properties of the ligand-binding
pocket of CDK1, CDK5, GSK-3α, GSK-3β and PERK. Water mapping calculations are useful in
identifying the essential and artificial active site’s water molecules. As well these calculations
help in suggesting ligand substitutions. Proper protein and ligand preparations are required
before starting SZMAP calculation. FIXDUPATOMNAMES292 was used to standardize atom
types & names and to remove duplicated atom names. REDUCE293 and PrepWizard294, 295 were
used to explicitly add hydrogen atoms to the protein–ligand complex. MKHETDICT292 was used
to generate the PDB heterogen dictionary that is required by REDUCE to allow for proper ligand
protonation. All OH and SH groups of all amino acids, and the CH3 of methionine were allowed
to rotate. The structures were then split into protein and ions in one file and ligand in another file
using PCH292. AmberFF94296 forcefield and charges were used to assign the partial charges for
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amino acids and AM1BCC297 was used for the small organic compounds. We calculated the
regions of solvent stabilization and destabilization of the protein-ligand complex, apoprotein and
the ligand, were calculated using an explicit water molecules probe. The excess free energy was
determined for the water molecules and in particular those that can be displaced by the ligand298.
In general, SZMAP algorithm292 for studying the thermodynamic properties of the active site is
based on a semi-continuum solvent approach in which water molecules will be desolvated by the
effect of the solute (ligand molecule) and each of such water molecules is supposed to have
many possible orientations. The ones with their protons closer to the solute are believed to be
more solvated. By sampling enough orientations, the partition function can be calculated as
(Equation 1):
N orient

Q=

∑e

−

Ej
kT

(1)

j=1

where Q is the partition function, Ej is the energy value for each probe water orientation j. Ej is
given as (Equation 2):
*
E j = PBint (P : W ) + Pdesolv
+ Wdesolv + VDW[ j = 1...N orient ] (2)

Ej is the sum of the Poisson-Boltzmann (PB) protein:water Coulombic interaction energy
[PBint(P:W)], protein desolvation (P*desolv, for speed purposes, it is computed once per grid point
using a spherical united-atom representation of the probe water), water desolvation (Wdesolv)
penalties and the van der Waals energy (VDW[j=1…Norient]). FRED shape scoring function is
used to provide positions of water that would make contact with protein and remove points that
VDW would disallow. For each water orientation, a potential field is calculated throughout the
protein. The rotationally averaged free energy of each water orientation is calculated. The
probability292 (prob) of each water orientation (j) is given by Equation 3:
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−

prob j =

E
kT

e
(3)
Q

The entropic and enthalpic contributions are calculated, the probe water orientation
entropy (Equation 4), free energy (Equation 5) and enthalpy (Equation 6) differences from
continuum water are calculated by:
TΔS = (−kT ∑

N orient
j=1

prob j ln prob j ) − kT ln N orient (4)

ΔG = −(kT lnQ − kT ln N orient ) (5)
ΔH = ΔG + TΔS (6)
GAMEPLAN292 was then used to provide suggestions for ligand substitutions to improve
its binding affinity to the protein target. This lead optimization plans would be of value to
increase the hit rate to identify more active hits.

3.3. Results and discussion
3.3.1. Structural analysis
The kinase domain is conserved and protein alignment of the crystal structures of PERK
(PDB code: 4G31213), CDK5 (PDB code: 1UNL143), GSK-3β (PDB code: 1Q41167) and 3D
models of CDK1, and GSK-3α showed similar ligand binding pockets (Figure 3.1). The structure
of kinases shows several conserved structural motifs and domains that contribute to their
function and ligand binding. The kinase domain is made up of about 300 residues organized in
two domains (N- and C-lobes) as eight α-helices (αB-αI) and nine strands (β1-β9) (Figure 3.2).
The N-terminal (N-lobe) domain is composed of about 80 amino acids and formed of five antiparallel β-sheets and two α-helices (β1-β2-β3-αB-αC-β4-β5)299. The C-terminal (C-lobe) domain
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has about 200 amino acids residues and contains six major α-helices (αD-αI) and four β-sheets
(β6-β9).
Kinases contain some conserved structural domains and motifs including G-loop, αChelix, hinge region, HRD domain, activation loop and DFG region. Glycine rich loop (G-loop, Ploop or Walker A motif) is highly flexible loop and is located between β1 and β2 strands in the
N-lobe. G-loop consists of about 10 amino acid residues with the general sequence of
HGXGX(Y/F)GXVH motif, where H for any hydrophobic amino acid residue such as Gly, Ala,
Val, Leu, Ile, Pro, Phe, Met, and Trp. G for glycine, X for any amino acid, Y for tyrosine, F for
phenylalanine and V for valine residues299.
In CDK5, G-loop consists of ILe10, Gly11, Glu12, Gly13, Thr14, Tyr15, Gly16, Thr17
and Val18 (Figure 3.3). The G-loop of GSK-3β contains Ile62, Gly63, Asn64, Gly65, Ser66,
Phe67, Gly68, Val69 and Val70 (Figure 3.4). PERK has a G-loop consisting of Leu598, Gly599,
Arg600, Gly601, Gly602, Phe603, Gly604, Val605 and Val606 (Figure 3.5).
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Figure 3.1. Structure alignment of CDK1 (3D model, blue), CDK5 (PDB code 1UNL, red),
GSK-3α (3D model, yellow), GSK-3β (PDB code: 1Q41, green) and PERK (PDB code: 4G31,
pink).
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Figure 3.2. Cartoon representation of the structural elements of protein kinases using CDK5 as
an example (PDB code: 1UNL), showing the N- and C-lobes.
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Figure 3.3. The G-loop of CDK5. The amino acid residues representing the G-loop are shown as
sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green loops.

Figure 3.4. The G-loop of GSK-3β. The amino acid residues representing the G-loop are shown
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green
loops.
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Figure 3.5. The G-loop of PERK. The amino acid residues representing the G-loop are shown as
sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green loops.

The conserved lysine residue300 is positioned at the end of β3 strand of the N-lobe and
forms salt-bridge with the conserved glutamate, which is placed at the middle of αC-helix. The
distance between Lys33 and Glu51 is about 3.0 Å in CDK5 (Figure 3.6) which similar to that of
GSK-3β (Lys85…Glu97) (Figure 3.7). However, the distance between Lys662 and Glu639 is 7.5
Å in PERK (Figure 3.8).
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Figure 3.6. Conserved lysine of CDK5. The amino acid residues representing the conserved Lys
are shown as sticks. The slat-bridge between Lys and Glu is shown as a yellow line. The protein
is represented as cartoon with yellow α-helices, red β-sheets and green loops.
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Figure 3.7. Conserved lysine of GSK-3β. The amino acid residues representing the conserved
Lys are shown as sticks. The slat-bridge between Lys and Glu is shown as yellow line. The
protein is represented as cartoon with yellow α-helices, red β-sheets and green loops.
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Figure 3.8. Conserved lysine of PERK. The amino acid residues representing the conserved Lys
are shown as sticks. The slat-bridge between Lys and Glu is shown as yellow line. The protein is
represented as cartoon with yellow α-helices, red β-sheets and green loops.

The activation loop (A-loop or T-loop) of kinases is the amino acid residues that are the
two conserved motifs DFG and APE301. A-loop has the DFG-loop at its N-terminal part
preceding the phosphorylation site amino acid residue, which could be serine, threonine, or
tyrosine, and at the C-terminal region there is the APE motif. The activation segment of CDK5
begins with the conserved DFG motif (NFG in CDK5) till the APE domain, which is mutated to
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PPD in this kinase. The segment contains Mg2+ binding regions (DFG), the β9 strand, the
phosphorylation site, and the P+1 loop. CDK5 has an A-loop consisting of the following residues
Ala143, Asn144, Phe145, Gly146, Leu147, Ala148, Arg149, Ala150, Phe151, Gly152, Ile153,
Phe154, Val155, Arg156, Cys157, Tyr158, Ser159, Ala160, Glu161, Val162, Val163, Thr164,
Leu165, Trp167, Tyr168, Arg169, Pro170, Pro171 and Asp172 (Figure 3.9).

Figure 3.9. The A-loop of CDK5. The amino acids residues representing the A-loop are shown
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green
loops.

The A-loop of GSK-3β consists of the following amino acid residues; Asp200, Phe201,
Gly202, Ser203, Ala204, Lys205, Gln206, Leu207, Val208, Arg209, Gly210, Glu211, Pro212,
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Asn213, Val214, Ser215, Tyr216, Ile217, Cys218, Ser219, Arg220, Tyr221, Tyr222, Arg223,
Ala224, Pro225 and Glu226 (Figure 3.10). The A-loop PERK contains Asp954, Phe955, Gly956,
Leu957, Val958, Thr959, Ala960, Met961, Asp962, Gln963, Asp964, Glu965, Glu966, Glu967,
Gln968, Thr969, Val970, Leu971, Thr972, Pro973, Met974, Pro975, Ala976, Tyr977, Ala978,
Arg979, His980, Thr981, Gly982, Gln983, Val984, Gly985, Thr986, Lys987, Leu988, Tyr989,
Met990, Ser991, Pro992 and Glu993. In the experimental X-ray crystal structures of PERK, the
amino acids highlighted in yellow above are missing.

Figure 3.10. The A-loop of GSK-3β. The amino acid residues representing the A-loop are shown
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green
loops.

DFG regions302 (Figures 3.11-3.13) affect kinase conformation and hence the type of
enzyme inhibitor. Based on the published reports, the inactive kinase conformation (DFG-out) is
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because of a Phe turn of ~120°. Phosphorylation of Thr/Ser, or Tyr amino acids leads to kinase
activation to adopt DFG-in conformation and the A-loop will be moved away from the active site
aiding in substrate binding. The flipping of DFG in the inactive state leads to a 45° rotational
motion of the αC-helix disrupting the salt bridge between the conserved Lys and Glu (Figure 3.63.8).

Figure 3.11. DFG-loop of CDK5. The amino acid residues representing the DFG-loop are shown
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green
loops.
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Figure 3.12. DFG-loop of GSK-3β. The amino acid residues representing the DFG-loop are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.

Figure 3.13. DFG-loop of PERK. The amino acid residues representing the DFG-loop are shown
as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and green
loops.

108

Kinase domain is bilobar with a small N-lobe and a large C-lobe. The N-lobe contains the
nucleotide binding site and the C-lobe contains the substrate recognition site. The ATP and ATP
analogues bind to the deep cleft between the N- and C-lobes302. Most kinase inhibitors (Figures
3.14-3.16) bind to this cleft mostly aided by hydrophobic and hydrogen bonding types of
interactions.

Figure 3.14. The ligand binding pocket of CDK5, showing key amino acid residues involved in
the interaction ligands. The protein is represented as cartoon with yellow α-helices, red β-sheets
and green loops.
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Figure 3.15. The ligand binding pocket of GSK-3β, showing key amino acid residues involved
in the interaction ligands. The protein is represented as cartoon with yellow α-helices, red βsheets and green loops.

Figure 3.16. The ligand binding pocket of PERK, showing key amino acid residues involved in
the interaction ligands. The protein is represented as cartoon with yellow α-helices, red β-sheets
and green loops.
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The kinase binding pocket303 is usually divided into a set of sub-pockets, named: adenine
(AP), ribose (RP), phosphate (PP), solvent (SP), back (HPI) and hydrophobic allosteric (HPII).
The sub-pocket of adenine is generally hydrophobic in nature and composed of the hinge region
and gatekeeper residue (GK). The amino acid residues of β1, β2, β3, αC, β4, and β7 surround the
AP and contribute to the hydrophobicity. The size of the GK residue regulates the size of the AP
derivative, and thus plays a role in kinase specificity. In CDK5 the GK is Phe80 that is larger
than those of GSK-3β (Leu132) and PERK (Met888) (Figures 3.17-3.19).

Figure 3.17. The GK of CDK5. The amino acid residues representing the GK−1 to GK+3 are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.
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Figure 3.18. The GK residue of GSK-3β. The amino acid residues representing the GK−1 to
GK+3 are shown as sticks. The protein is represented as cartoon with yellow α-helices, red βsheets and green loops.

Figure 3.19. The GK of PERK. The amino acid residues representing the GK−1 to GK+3 are
shown as sticks. The GK residue is shown in two orientations. The protein is represented as
cartoon with yellow α-helices, red β-sheets and green loops.
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The hinge region (Figures 3.20-3.22) is the linker between β5 strand and αD helix and
contains amino acid residues starting from GK+1 to GK+3 in relation to the location of the GK
residue303. The adenine of ATP forms hydrogen bonds with the hinge region. Till date, most of
the discovered kinase inhibitors are found to form one to three hydrogen bonds with the amino
acids residing in the hinge region mimicking the hydrogen bonds formed by the adenine group.

Figure 3.20. The hinge region of CDK5. The amino acid residues representing the hinge region
are shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.
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Figure 3.21. The hinge region of GSK-3β. The amino acid residues representing the hinge
region are shown as sticks. The protein is represented as cartoon with yellow α-helices, red βsheets and green loops.

Figure 3.22. The hinge region of PERK. The amino acid residues representing the hinge region
are shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.
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The Phe amino acid residue of the DFG motif shows hydrophobic interactions with the
αC-helix and His–Arg–Asp (HRD) motif303 (Figures 3.23-3.25). This motif is highly conserved
in protein kinases. Based on the degree of conservation Asp member is the most conserved
amino acid amongst the three. The HRD aspartate aids in orienting the P-site group of the
peptide substrate. The Arg residue of the HRD motif is found only in the eukaryotic kinases. The
HRD Arg supports the geometry of the A-loop for the required phosphorylation.

Figure 3.23. The HRD motif of CDK5. The amino acid residues representing the HRD are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.
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Figure 3.24. The HRD motif of GSK-3β. The amino acid residues representing the HRD are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.

Figure 3.25. The HRD motif of PERK. The amino acid residues representing the HRD are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.
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CDK5 varies from other CDK family members in many aspects including its activation
by p35 and p39 rather than cyclins. The interface between p35/p25 and the active CDK5 is close
to other CDK family members, suggesting similar activation mechanism143. Hyperactivation of
CDK5 when it binds with p25 leads to hyperphosphorylation of tau in AD. Exposure to Aβ
peptides leads to truncation of p35 to p25 that is a CDK5 activator. p25 protein binds selectively
with CDK5 (Figures 3.26-3.28) and does not bind or activate any other member of the CDK
family143.

Figure 3.26. The interface of CDK5-p25. The Cα of the residues at the interface are shown as
spheres. The amino acid residues of CDK5 at the interface are colored orange, and that of p25 as
pink. The protein is represented as cartoon with yellow α-helices, red β-sheets and green loops.
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Figure 3.27. The interface of CDK5-p25. The amino acid residues of CDK5 at the interface are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.

Figure 3.28. The interface of CDK5-p25. The amino acid residues of p25 at the interface are
shown as sticks. The protein is represented as cartoon with yellow α-helices, red β-sheets and
green loops.
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The six sub-pockets of the kinase active site are previously mentioned as adenine (AP),
ribose (RP), phosphate (PP), solvent (SP), back (HPI) and hydrophobic allosteric (HPII). The
sub-pocket HPI is hydrophobic in nature. The GK residue controls the entry of the inhibitor to
the HPI sub-pocket. The hydrophilic sub-pocket (RP) is adjacent to the hydrophobic sub-pocket
AP, the solvent exposed pocket (SP), and G-loop (Figure 3.27). The PP sub-pocket is close to
Asp of the DFG-loop. The hydrophilic sub-pocket SP is adjacent to the terminal end of hinge
region. The hydrophobic allosteric sub-pocket (HPII) is not conserved and can be targeted for
kinase specificity. We analyzed the protein-ligand interactions for CDK5, GSK-3β and PERK
(Figures 3.29-3.32, and Tables 3.1-3.1) using one crystal structure for each as an example.

Figure 3.29. The six sub-pockets of the kinase
binding site using CDK5 (PDB code 4AU8289)
HPII

for illustration, adenine (AP), ribose (RP),
HPI

phosphate (PP), solvent (SP), back (HPI) and
hydrophobic allosteric (HPII). The amino acids
AP

PP

participating in ligand interactions are shown as
sticks Tyr15 (G-loop), Asp144-Gly146 (DFG),
Phe80 (GK), Glu81-Asp84 (Hinge), Lys33

RP

(Conserved Lys), and Glu51 (αC-helix).

SP
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Figure 3.30. The CDK5-ligand interaction (PDB code: 4AU8289).
Table 3.1. Ligand Interactions Report (PDB code: 4AU8289).
Ligand
N7
S13
C14
N18
N18
N18
N18
O16
O16
O17
O17
N18
5-ring

Receptor
O HOH2089(A)
O Cys83(A)
O HOH2089(A)
O Ile10(A)
OD2 Asp86(A)
O HOH2101(A)
O HOH2102(A)
O HOH2095(A)
O HOH2254(A)
CA Gln85(A)
N Asp86(A)
O HOH2101(A)
CG1 Val18(A)

Interaction
H-donor
H-donor
H-donor
H-donor
H-donor
H-donor
H-donor
H-acceptor
H-acceptor
H-acceptor
H-acceptor
H-acceptor
pi-H
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Distance
2.78
3.06
3.43
2.76
2.91
3.56
3.85
3.57
3.25
3.43
3.03
3.56
3.92

E (kcal/mol)
-3.1
-0.3
-1.1
-5.9
-3.8
-1.1
-1.2
-0.7
-1.5
-0.8
-2.1
-0.7
-0.6

Figure 3.31. GSK-3β-ligand interaction (PDB code: 4AFJ304).
Table 3.2. Ligand Interactions Report (PDB code: 4AFJ304).
Ligand

Receptor

Interaction

C11

O Asp133(A)

H-donor

3.04

-1.9

N16

O Val135(A)

H-donor

2.65

-0.9

N12

N Val 135(A)

H-acceptor

3.36

-1.6
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Distance

E (kcal/mol)

Figure 3.32. PERK-ligand interaction (PDB code: 4G31213).

Table 3.3. Ligand Interactions Report (PDB code: 4G31213).
Ligand

Receptor

Interaction

Distance

E(kcal/mol)

N03

O GLN888(A)

H-donor

2.82

-2.6

N3

O HOH1355(A)

H-acceptor

2.87

-2.3

O4

O HOH1356(A)

H-acceptor

3.02

-2.6

N04

N CYS890(A)

H-acceptor

2.79

-4.5
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3.3.2. Active site hydration
Protein-ligand complex is usually stabilized by solvation and desolvation of the active
site. In the apoprotein water molecules are in ordered state and upon ligand binding some of the
waters displaced to accommodate the ligand. Some of the water molecules are buried and
required to maintain the protein geometry. These water molecules are conserved. Water
molecules in the active site form hydrogen bonds with or are displaced by the ligand. To define
the conserved water molecules in the studied kinases, we averaged all water molecules from the
experimentally solved crystal structures. Water molecules that showed mobility of less than 2.0
Å are clustered and the degree of conservation is then calculated.
In case of CDK5, six PDB structures [PDB codes: 1H4L305, 1UNG142, 1UNH142,
1UNL142, 2O0G306, 4AU8289, Figure (3.33)] are used in this calculation because they have
resolution of ≤ 3.0 Å. All kinase chains are extracted and considered in this study (i.e. we used
12 kinase chains). We found 32 water molecules with conservation degrees of 0.66 to 1.00
(Figures 3.34). Three water molecules are found in the active site forming hydrogen bonding
network with Thr14, Lys33, Glu51, His124, Ala143, Asp144, Phe145 and Gly146 (Figures 3.353.36). These conserved waters are believed to play important roles in ligand binding and will be
necessary to consider them in docking experiments and virtual screening calculations.
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Figure 3.33. Superimposed CDK5 structures showing the conserved water molecules.

Figure 3.34. CDK5 conserved water molecules. Waters are colored based on the degree of
conservation from red to blue. Degree of water conservation ranges from 0.667 to 1.00
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Figure 3.35. CDK5 conserved water molecules. There are three conserved active site waters
having several hydrogen bonds with the surrounding amino acids.

Figure 3.36. CDK5 conserved water molecules. The active site waters in the aligned structures.
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In case of GSK-3β, we retrieved 44 PDB structures from the protein databank repository
(PDB codes: 1GNG307, 1H8F308, 1I09308, 1J1B245, 1J1C245, 1O9U309, 1PYX167, 1Q3D167,
1Q3W167, 1Q41167, 1Q4L167, 1Q5K168, 1R0E169, 1UV5310, 2JLD170, 2OW3311, 3DU8172, 3F7Z312,
3F88312, 3GB2173, 3I4B174, 3L1S175, 3PUP313, 3Q3B176, 3SAY314, 3SD0177, 3ZDI178, 3ZRK179,
3ZRL179, 3ZRM179, 4ACC180, 4ACD180, 4ACG180, 4ACH180, 4AFJ304, 4B7T315, 4DIT316, 4J1R317,
4J71317, 4NM0318, 4NM3318, 4NM5318, 4NM7318 and 4NU1318) with resolution of ≤ 3.0 Å (Figure
3.37). These structural files contain 77 kinase chains and used for calculating the conserved
water molecules. We found 45 conserved water molecules with degree of conservation of 0.5 to
0.9 (Figure 3.38). Five water molecules are located in the active site forming a network of
hydrogen bonding with several amino acid residues including His179, Arg180, Asp181, Glu197,
Asp200, Phe201, Gly202, Ser203, Ala204, and Cys218 (Figures 3.39-3.40). In this case the
higher number of crystal structures signifies the results. The five conserved water molecules
should be considered while performing the second step of virtual screening.

Figure 3.37. Superimposed GSK-3β structures showing the conserved water molecules.

126

Figure 3.38. GSK-3β conserved water molecules. Waters are colored based on the degree of
conservation from red to blue.

Figure 3.39. GSK-3β conserved water molecules. There are five conserved active site waters
having several hydrogen bonds with the surrounding amino acids.
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Figure 3.40. GSK-3β conserved water molecules. The active site waters in the aligned
structures.

In case of PERK, we used 9 PDB structures (PDB codes: 4G31213, 4G34213, 4M7I214,
4X7H214, 4X7J214, 4X7K214, 4X7L214, 4X7N214 and 4X7O214) with resolution of ≤ 3.0 Å (Figure
3.41). The PDB structural files contain 9 kinase chains. We used the kinase chains in calculating
the conserved water molecules. The conserved water molecules in PERK were calculated as 28
with degree of conservation of 0.66 to 1.00 (Figure 3.42). Four water molecules are located in
the active site and involved in extensive hydrogen bonding with several amino acid residues in
the ligand pocket including Gly599, Arg600, Lys621, Ile650, Val651, Asp936, Asn941, Val952,
Gly953, Asp954, Phe955 and Gly956 (Figures 3.43-3.44). The four conserved water molecules
will be considered while performing the second step of virtual screening.
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Figure 3.41. Superimposed PERK structures showing conserved water molecules.

Figure 3.42. PERK’s conserved water molecules. Waters are colored based on the degree of
conservation from red to blue.
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Figure 3.43. PERK’s conserved water molecules. There are four conserved active site waters
having several hydrogen bonds with the surrounding amino acids.

Figure 3.44. PERK’s conserved water molecules. The active site waters in the aligned structures.
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3.3.3. Water mapping
We scanned the ligand binding pockets for accommodation of water molecules using the
thermodynamic properties of the different regions of the active site as a monitor. We used the
homology models generated for CDK1 and GSK-3α in complex with one of the docking poses of
our hit compounds. For CDK5, GSK-3β and PERK, we used their already solved crystal
structures. We used SZMAP to define the region of the active site that can hold water with high
and low residence. The positions in the active site that favors water molecules are suitable
locations and allow room for polar ligand modifications. These water molecules if not in the
stabilization regions of the protein, can be displaced with polar functional groups. Stabilization
waters and waters allowed for displacement provide anchors for hydrogen bonds and
electrostatic interactions with the polar substituents. The places of the active sites that are
described as less thermodynamically stable positions for water molecules are suitable for nonpolar and hydrophobic modifications. Upon binding with ligands we observed changes in the
thermodynamic properties of the active site change for ligand accommodation. Some water
molecules were displaced with ligand functional groups. Some waters showed modified
coordinates to participate in hydrogen bonds with ligand groups.
In CDK1 we identified thermodynamically stable regions in the apoprotein structure
(Figure 4.45). The water map shows large yellow surface, which indicates the high polarity of
the active site. There are small patches of red surface close to the central part of αC-helix. The
yellow surface represents the regions of high water occupancy, and the red regions for low water
occupancy. Upon ligand binding, SZMAP represented only the regions of the water map, which
are in contact with ligand. The polar groups flank perfectly with the yellow surface and the
hydrophobic groups flank with the red surface (Figure 3.46). The regions of the active site that
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show highest van der Waals interaction are found close to heterocyclic ring of the ligand and to
αC-helix (Figure 3.47).
From SZMAP calculations, there are 42 clusters of water molecules in the active site
(Figure 3.48) with ∆G of 0.82 to -10.89 kcal/mol. About 16 water molecules are overlapping
with the ligand atoms and displaced or modified the position to accommodate the ligand (Figure
3.49). The water molecules that are predicted to be in the protein-ligand complex (33 waters with
∆G of 0.76 to -11.13 kcal/mol) are displayed in Figure 3.50. The ligand binding pockets showed
a chain of favorable and unfavorable water positions (Figure 3.51).
The hydrophobic elements are unfavorable for ligand binding in the stable hydration site
but are favorable in the unstable sites. However, the information inferred from each specific
hydration site is based on the protein environment (Figure 3.52). For instance, the red water
cluster (Figure 3.52) shows unstable hydration site with high ∆G and excess entropy. On the
other hand this site shows strong hydrogen bonds to the surrounding amino acid residues
(Leu134 and Ala145). This observation suggests the instability of hydrophobic group in this
position and the activity is proposed to increase by adding polar group to displace this water
molecule. In general, we defined 9 water molecules in an area of 5.00 Å around the ligand with
occupancies ranging from 0.3 to 0.98 (Figure 3.53 and Table3.4). The ones with high entropy
values are forming more contacts with the surrounding protein than with bulk water. The waters
that show more negative ∆G are in stable hydration site and can be utilized either for lead
optimization or target specificity.
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Figure 3.45. A thermodynamic map of CDK1. The regions of negative free energy are shown as
yellow surface and the regions of positive free energy are shown as red surface.

Figure 3.46. A thermodynamic map of CDK1 after ligand binding showing how the ligand
interacts favorably or unfavorably with the amino acid residues in the active site.
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Figure 3.47. The region of the active site of CDK1 that shows van der Waals interactions.

Figure 3.48. The water clusters in CDK1. Water clusters overlapping with the ligand are
displaced. Waters are colored according to ∆G 0.82 (red) to −10.89 (blue).
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Figure 3.49. Waters clusters of CDK1 that are displaced due to ligand binding. Waters are
colored according to ∆G −1.15 (red) to −7.67 (blue).

Figure 3.50. Water clusters of CDK1 in the protein-ligand complex. Waters are colored
according to ∆G from +0.76 (red) to −11.13 (blue).
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Figure 3.51. The water chains in the active site of CDK1. Water clusters are shown as spheres,
colored based on the ∆G value; from red (positive) to green (negative). Protein is displayed as
cartoon with red α-helices, grey loops and cyan β-sheets.
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Figure 3.52. Each hydration site provides specific knowledge based on the protein environment
of CDK1. The red spheres (the unstable water clusters) participate in strong hydrogen bonding
networks with the amino acid residues and can be displaced by hydrophilic groups. The green
spheres (stable hydration sites) show strong hydrogen bonds with both Asp146 and Thr14,
suggesting hydrophilic substitutions would improve the ligand activity.
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Figure 3.53. The water sites within 5 Å distances of the ligands in CDK1.

Table 3.4. Thermodynamic properties of water sites 5 Å around the ligands of CDK1.
Site
Occupancy
∆H
-T∆S
∆G
HB(W)
W4
0.98
-7.36
5.02
-2.34
0.05
W8
0.94
2.46
4.41
6.87
0.09
W10
0.93
-1.23
3.88
2.65
1.48
W23
0.81
-7.34
3.28
-4.06
1.16
W61
0.42
-1.76
1.73
-0.03
0.6
W73
0.36
0.36
0.98
1.34
2.45
W75
0.34
7.01
0.99
8
0.84
W81
0.32
-0.37
1.1
0.73
1.01
W86
0.3
1.17
0.88
2.05
2.29
HB: Hydrogen bonds, (W) with water, (P) with protein and (L) with ligand
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HB(P)
1.96
1.25
0.97
1.06
1.85
0
0
0.87
0

HB(L)
0
0
0
0.91
0
0
0.05
0
0

We performed thermodynamic studies for other targets under investigation. We examined
the crystal structure of CDK5 (4AU8289). CDK5 displayed a stable hydration site close to αChelix (Figure 3.54). There is continuous chain of stable waters in the active site suggesting the
need of strong polar substituents. The thermodynamic characteristics of the ligand affect the
regions of the watermap (Figure 3.55) to accommodate ligand binding. The regions of high van
der Waals interactions are shown close to the N- and C-terminal of αC-helix (Figure 3.56). The
water clusters are calculated in the apoprotein (Figure 3.57) to find out which water molecule
will be displaced upon ligand binding (Figure 3.58). The distribution of waters is calculated in
the protein-ligand complex (Figure 3.59).

Figure 3.54. A thermodynamic map of CDK5. The regions of negative free energy are shown as
yellow surface and the regions of positive free energy are shown as red surface.
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Figure 3.55. A thermodynamic mapping of CDK5 after ligand binding showing how the ligand
interacts favorably or unfavorably with the amino acid residues in the active site.

Figure 3.56. The regions of the active site of CDK5 that show van der Waals interactions.
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Figure 3.57. The water clusters in CDK5. Water clusters overlapping with the ligand are
displaced. Waters are colored according to ∆G from +0.84 (red) to −8.59 (blue). Forty-five water
sites are displayed. Three native waters within 5 Å of the ligand are shown as grey spheres

Figure 3.58. Waters clusters of CDK5 that are displaced due to ligand binding. Waters are
colored according to ∆G from +0.84 (red) to −6.35 (blue). Twelve water sites are displayed.
Three native waters are shown as grey spheres.

141

Figure 3.59. Water clusters in the protein-ligand complex of CDK5. Waters are colored
according to ∆G from 1.28 (red) to −10.18 (blue). A total of water sites are displayed. Three
native waters are shown as grey spheres.

We examined the active site of the homology model of GSK-3α, which showed stable
hydration sites close to αC-helix (Figure 3.60) and small discrete patches of unstable sites in the
ligand binding pockets. We observed a similar continuous chain of stable watermap in the active
site as in case of CDK5, which recommends polar substituents in GSK-3α modulators. Upon
ligand binding the hydration sites will accommodate the ligand by water displacement (Figure
3.61). We observed small patches with van der Waals interactions around the ligand (Figure
3.62). We calculated the water clusters in the apoprotein (Figure 3.63) to find out which water
molecule will be displaced upon ligand binding (Figure 3.64). The water distribution in the
active site was calculated in the protein-ligand complex (Figure 3.65).
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Figure 3.60. A thermodynamic map of the GSK-3α model. The regions of negative free energy
are shown as yellow surface and the regions of positive free energy are shown as red surface.

Figure 3.61. A thermodynamic map after ligand binding to GSK-3α, showing how the ligand
interacts favorably or unfavorably with the amino acid residues in the active site.
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Figure 3.62. The regions of the active site of GSK-3α that show van der Waals interactions.

Figure 3.63. The water clusters in the apoprotein of GSK-3α. Water clusters overlapping with
the ligand are displaced. Waters are colored according to ∆G from −1.73 (red) to −11.21 (blue).
A total of 32 water sites are displayed as spheres. Ligand is shown as sticks and protein as
cartoon.
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Figure 3.64. Waters clusters of GSK-3α that are displaced due to ligand binding. Waters are
colored according to ∆G −2.08 (red) to −4.31 (blue). A total of 12 water sites are displayed.

Figure 3.65. Water clusters in the protein-ligand complex of GSK-3α. Waters are colored
according to ∆G from 0.78 (red) to −11.27 (blue). A total of 29 water sites are displayed.
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We examined the binding pocket of the crystal structure of GSK-3β (PDB code:
4ACC180). The ligand binding pockets of GSK-3β exhibited stable hydration sites close to αChelix, β1 and β2 strands (Figure 3.66). Small patches of unstable hydration sites are observed in
the pocket. The water clusters forms a continuous chain of stable hydration sites. Polar functional
groups are recommended in GSK-3β modulators. Ligand binding leads to water displacement
(Figure 3.67). Two small patches with van der Waals interactions are around the ligand (Figure
3.68). We calculated the water clusters in the apoprotein (Figure 3.69) to find out which water
molecule might be displaced upon ligand binding (Figure 3.70). The water distribution in the
active site was calculated in the protein-ligand complex (Figure 3.71).

Figure 3.66. A thermodynamic map of GSK-3β. The regions of negative free energy are shown
as yellow surface and the regions of positive free energy are shown as red surface.
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Figure 3.67. A thermodynamic mapping of GSK-3β after ligand binding showing how the ligand
interacts favorably or unfavorably with the amino acid residues in the active site.

Figure 3.68. The regions of the active site of GSK-3β that show van der Waals interactions.
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Figure 3.69. The water clusters of GSK-3β. Water clusters overlapping with the ligand are
displaced. Waters are colored according to ∆G from −1.51 (red) to −10.74 (blue). A total of 47
water sites are displayed as spheres. Ten native waters are shown as grey spheres. Ligand is
shown as sticks and protein as cartoon.
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Figure 3.70. Waters clusters of GSK-3β that are displaced due to ligand binding. Waters are
colored according to ∆G from −1.86 (red) to −5.17 (blue). Twelve water sites are displayed. Ten
native waters are shown as grey spheres.

Figure 3.71. Water clusters in the protein-ligand complex of GSK-3β. Waters are colored
according to ∆G from −1.5 (red) to −10.72 (blue). Twenty-nine water sites are displayed. Ten
native waters are shown as grey spheres.
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We studied the binding pocket of the crystal structure of PERK (PDB code: 4G31213).
The ligand binding pockets PERK exhibited stable hydration sites close to αC-helix (Figure
3.72). Small patches of unstable hydration sites are observed in the pocket close to the middle
part of αC-helix. The watermap forms a broken chain of stable hydration sites. Polar and nonpolar functional groups are recommended for PERK modulators. Ligand binding leads to water
displacement (Figure 3.73). Three small patches of high van der Waals interactions are around
the ligand (Figure 3.74). We calculated the water clusters in the apoprotein (Figure 3.75) to find
out which water molecule will be displaced upon ligand binding (Figure 3.76). The water
distribution in the active site was calculated in the protein-ligand complex (Figure 3.77).

Figure 3.72. Thermodynamic map of PERK. The regions of negative free energy are shown as
yellow surface and the regions of positive free energy are shown as red surface.
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Figure 3.73. Thermodynamic map of PERK after ligand binding, showing how the ligand
interacts favorably or unfavorably with the amino acid residues in the active site.

Figure 3.74. The regions of the active site of PERK that show van der Waals interactions.
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Figure 3.75. The water clusters in PERK. Water clusters overlapping with the ligand are
displaced. Waters are colored according to ∆G from 1.48 (red) to −10.79 (blue). Thirty-eight
water sites are displayed as spheres. Five native waters are shown as grey spheres. Ligand is
shown as sticks and protein as cartoon.
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Figure 3.76. Waters clusters of PERK, which were displaced due to ligand binding. Waters are
colored according to ∆G from −1.58 (red) to −5.95 (blue). Ten water sites are displayed. Five
native waters are shown as grey spheres.

Figure 3.77. Water clusters in the protein-ligand complex of PERK. Waters are colored
according to ∆G from 2.16 (red) to −10.79 (blue). Thirty-five water sites were displayed. Five
native waters are shown as grey spheres.
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To improve the binding affinity of GSK2606414213 (Figure 3.78) with PERK, several
modifications can be attempted such as adding polar (Figures 3.79 and 3.80), or small non-polar
substituents on the phenyl ring. Also, polar substituent on the yellow sites of the indole (Figure
3.80) will improve the binding.

Figure 3.78. The ligand binding pockets of PERK showing GSK2606414 as large sticks and the
surrounding amino acid residues are displayed as sticks.
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Figure 3.79. Left, the neutral free energy difference grid at the coordinate of the ligand. The
energy ranges from orange (favorable for polar) to purple (favorable for non-polar). Middle,
matching and mismatching of the ligand with the thermodynamics of the active site. The ligand
matches the active site properties, some groups are more favorably should be hydrophobic but in
general there is no mismatch. Left, the regions of the ligand (spheres) that can accommodate
polar substituents to improve the binding affinity.

Figure 3.80. Left, the regions of the ligand that
accommodate non-polar substituents such as F and CH3.
Right, the regions that accommodate other types of nonpolar substituents.

155

3.4. Summary
We studied the common structural motifs and domains of GSK-3β, CDK5 and PERK
using the Conserved Domain Database. The identified common structural features included Gloop, αC-helix, hinge region, HRD domain, activation loop and DFG region. Further, we
identified the conserved water molecules in GSK-3β, CDK5 and PERK through calculating the
degree of water conservation by superimposing the crystal structures of the kinase domains using
the backbone as the frame reference. Furthermore, we analyzed the thermodynamic properties of
the ligand-binding pocket of CDK1, CDK5, GSK-3α, GSK-3β and PERK. We were able to
define the regions of the active site that can accommodate water molecules. These water
molecules, if not in the stabilization regions of the protein, could be displaced upon ligand
binding. The locations in the active site that favor water molecules are suitable places for ligand
modifications with polar functional groups. The places of the active sites that were described as
less thermodynamically stable positions for water molecules should be suitable for non-polar and
hydrophobic modifications. Stabilization waters and displaceable waters provided clues for
possible hydrogen bonds and electrostatic interactions with small molecules.
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CHAPTER 4. STUDY OF THE PROTEIN-LIGAND INTERACTIONS OF CDK1, CDK5,
GSK-3α, GSK-3β AND PERK USING MOLECULAR DYNAMICS SIMULATIONS

Manal A. Nael and Robert J. Doerksen
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4.1. Introduction
In this chapter, we investigated the protein-ligand interactions of CDK1, CDK5, GSK-3α,
GSK-3β and PERK using molecular dynamic (MD) simulations. We studied the important
interactions that significantly affect ligand binding to protein targets including hydrogen bonds,
hydrophobic, ionic, π-cation, π-π contacts and interactions through and involving water bridges.
Ligands properties such as intramolecular hydrogen bond formation, solvent accessible surface
area and polar surface area were calculated.
Since binding with a regulatory protein is essential for CDK5 activity319, we also studied
the protein-protein interaction profile of CDK5 with its regulatory subunit. P35 is most well
studied CDK5 regulatory protein. It is a 35-kDa protein and consists of 307 amino acids. Studies
showed that p35 could be divided into two regions named p10 and p25. The p25 region is the Cterminal and comprises 209 amino acids. P25 is a stronger CDK5 activator because it has longer
half-life than P35 and it is more cellular localized319. High calcium concentration associated with
deposition of Aβ activates the cleavage of p35 to p25, resulting in the formation of the
hyperactive CDK5/p25 complex. In this study, we reported the protein-protein interactions
between CDK5 and p25. Small molecules, which target this interaction, may provide a potential
therapeutic benefit for AD319.
In these studies, we used the 3D models that were prepared for CDK1 and GSK-3α (cf.
Chapter 2). In case of the other kinases we utilized an X-ray crystal structures [for CDK5 (PDB
code: 3O0G145), for GSK-3β (PDB code: 4ACC180) and for PERK (PDB code: 4G31213)]. We
decided to use a protein-ligand complex for each enzyme in order to define their interaction
profiles.
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4.2. Methods
4.2.1. Protein structure preparation.
The protein-ligand complexes were prepared using the Protein Preparation Wizard of
Schrödinger package294, 295. For the crystal structures we retained the water molecules within 5 Å
around the bound ligand. Missing hydrogen atoms were added, bond orders were corrected, and
missing side chains and loops were completed using Prime217-219. Water orientations were
sampled and hydrogen bonds were assigned. The structures were subjected to a series of energy
minimizations using OPLS2005 force field. The IMPACT module was used for structure
refinement till the RMSD of the heavy atoms converged to 0.3 Å.

4.2.1. MD simulations
DESMOND320-323 software was used for the MD simulations. We used the OPLS-2005
force field. The protein structures were solvated with a TIP4P water model in orthorhombic
simulation box with dimensions of 90 Å x 90 Å x 9 Å. The calculated numbers of solvent
molecules were 10,047, 10810, 12940, and 10345 for CDK1, GSK-3α, GSK-3β and PERK
correspondingly. Sodium ions were added based on the total charge of each protein. In case of
CDK5, we built three systems. One was for the kinase domain and it had 10052 solvent
molecules. Another system was for the p25 and we added 6022 solvent molecules. The third
system was for the CDK5-p25 complex with 13903 solvent molecules. Adding an appropriate
number of Na+ ions neutralized the net charge on the protein. The solvated proteins were then
energy-minimized with the DESMOND minimization algorithm with 5000 iterations and
convergence threshold of 1.0 kcal/mol/Å. Short MD simulations were performed before the
production step to achieve further structural relaxation of the minimized proteins. The relaxation
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step was 24 ps, and was performed using the NPT ensemble324 at a temperature of 300º K. The
production step was executed using the NPT ensemble, the Nosé−Hoover chain thermostat325,
and the Martyna−Tobias−Klein barostat326. A time step of 1 fs was used for the RESPA
integrator. The short range Coulombic interactions cutoff was set to 9 Å and the Particle Mesh
Ewald method327 was used to treat the long-range electrostatics. The M_SHAKE algorithm320-323
was used to constrain the hydrogen bonds. The snapshots (frames) were saved at intervals of 4.8
ps. The production step was carried out for 5 ns for each kinase under investigation and for 50 ns
for CDK5 and for the CDK5/p25 complex to obtain enough information about their proteinprotein interaction profile. We monitored the MD simulations for each protein structure under
investigation to get insights into protein structural conformation.

4.3. Results and discussion
The calculated Root Mean Square Deviation (RMSD) of the protein backbones during the
course of MD320-323 was 1-3 Å (Figures 4.1-4.5), which is acceptable for small, globular proteins.
RMSD is employed for measuring the atoms’ movement average of variation for each frame
with regard to the initial geometry. The formula used for calculating RMSD for frame x is the
following:

𝑅𝑀𝑆𝐷. =

1
𝑁

N

𝑟&K 𝑡.

− 𝑟& 𝑡M91

*
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where N is the number of atoms; tref is the reference time (first frame was considered as the
reference in our calculations and so reference time was t=0); and r' is the location of the atoms in
frame x after superposition on the first frame, where frame x is reported at time tx. This is
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repeated for all frames in the simulation trajectory.

Figure 4.1. The protein–ligand RMSD plots of CDK1. The figure shows the RMSD (on the
right Y-axis) for Cα's, side chains and heavy atoms (all atoms but not hydrogens). The Cα plot
shows the RMSD change of the protein (on the left y-axis) by aligning CDK1 MD frames on the
Cα's of the initial conformation. The ligand RMSD was calculated to check the stability of the
ligand in the binding pocket of CDK1. In the Ligand versus Protein plot, the RMSD of the ligand
heavy atoms were calculated by the placement of the CDK1–ligand complex on the CDK1
backbone of the first frame. The observed Ligand versus Protein RMSD values are lower than
those of the CDK1 backbones, which means the ligands are stable inside the binding sites. To
measure the internal fluctuation of ligand atoms inside the binding site, we plot Ligand versus
Ligand, which shows the RMSD of a ligand after superposition on its initial conformation.
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Figure 4.2. The protein–ligand RMSD plots for CDK5. The figure shows the RMSD for Cα's,
side chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot.

Figure 4.3. The protein–ligand RMSD plots of GSK-3α. The figure shows the RMSD for Cα's,
side chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot.
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Figure 4.4. The protein–ligand RMSD of GSK-3β. The figure shows the RMSD for Cα's, side
chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot.

Figure 4.5. The protein–ligand RMSD of PERK. The figure shows the RMSD for Cα's, side
chains, heavy atoms, the Ligand versus Protein plot and the Ligand versus Ligand plot.
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We calculated the Root Mean Square Fluctuation (RMSF) of the protein because it is
beneficial in describing the local changes along the protein chain and this allowed us to monitor
the regions of the proteins that mostly fluctuated during the course of MD simulations (Figures
4.6-4.10). The N- and C-terminal fluctuated the most compared to any other part of the protein.
The structured regions of the protein such as α helices and β strands were less fluctuating than
the unstructured part (loops) of the protein.
The RMSF320-323 can be calculated by the following formula:
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where T is the trajectory time over which the RMSF is calculated, tref is the reference time, ri is
the position of residue i on frame (t); r' is the position of atoms in residue i on the reference
frame, and the angle brackets indicate that the average of the square distance is taken over the
selection of atoms in the residue.

Figure 4.6. RMSF plot for CDK1. The figure shows the RMSF for Cα's, backbone, side chains
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green
vertical bars.
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Figure 4.7. RMSF plot of CDK5. The figure shows the RMSF for Cα's, backbone, side chains
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green
vertical bars.

Figure 4.8. RMSF plot of GSK-3α. The figure shows the RMSF for Cα's, backbone, side chains
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green
vertical bar.
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Figure 4.9. RMSF plot of GSK-3β. The figure shows the RMSF for Cα's, backbone, side chains
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green
vertical bars.

Figure 4.10. RMSF plot of PERK. The figure shows the RMSF for Cα's, backbone, side chains
and heavy atoms. Protein residues that show contacts with ligand atoms are marked with green
vertical bars.
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Then, we monitored the protein secondary structure elements (SSE) including α-helices
and β-strands throughout the development of MD simulation (Figure 4.11-4.15). Residues of
each protein were plotted with regard to the SSE distribution. The % helix, % strand, and % total
SSE for CDK1 were 24.37, 15.01, and 39.38, respectively. Those of CDK5 were 35.54, 8.51, and
44.05 respectively. Those of GSK-3α were 25.24, 16.15, and 41.39 respectively. Those of GSK3β were 23.80, 16.07, and 39.86 respectively. Those of PERK were 30.57, 17.02, and 47.59
respectively. We monitored the SSE composition for each frame over the course of the
simulation (Figure 4.16) and the assignment of the SSE of each residue over time (Figure 4.16).

Figure 4.11. The SSE distribution of CDK1. Cyan represents strands and orange represents
helices. The % helix, % strand, and % total SSE for CDK1 were 24.37, 15.01, and 39.38,
respectively.

Figure 4.12. The SSE distribution of CDK5. Cyan represents strands and orange represents
helices. The % helix, % strand, and % total SSE were 35.54, 8.51, and 44.05, respectively.
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Figure 4.13. The SSE distribution of GSK-3α. Cyan represents strands and orange represents
helices. The % helix, % strand, and % total SSE were 25.24, 16.15, and 41.39, respectively.

Figure 4.14. The SSE distribution of GSK-3β. Cyan represents strands and orange represents
helices. The % helix, % strand, and % total SSE were GSK-3β were 23.80, 16.07, and 39.86,
respectively.

Figure 4.15. The SSE distribution of PERK. Cyan represents strands and orange represents
helices. The % helix, % strand, and % total SSE were 30.57, 17.02, and 47.59, respectively.
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Figure 4.16. SEE composition of
CDK1 (first row, left), CDK5 (first
row, right), GSK-3α (second row,
left), GSK-3β (second row, right) and
PERK (third row).
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We examined the Ligand Root Mean Square Fluctuation (L-RMSF) by measuring the
position variations of all ligand's atoms. The ligand RMSF offers understandings on the energetic
effect of ligand functional groups on protein binding. The Fit Ligand on Protein (Figures 4.174.21) signifies the ligand atoms’ fluctuation and was calculated by fitting the protein-ligand
complexes on the protein backbones to measure ligand heavy atoms’ RMSF. To quantify the
internal atom fluctuation, the ligand in each frame is overlaid on the ligand in the first frame
followed by measuring the RMSF of ligand heavy atoms. The RMSF320-323 for atom i is
calculated by the following formula:

𝑅𝑀𝑆𝐹& =

1
𝑇

T

𝑟&K 𝑡

− 𝑟& 𝑡M91

*

UO)

where T is the MD simulation time, tref is the reference time, r is the position of atom i in the
reference at time tref, and r' is the position of atom i at time t after superposition on the reference
frame.
We inspected the protein-ligand contacts throughout the progression of the simulations.
Four types of interactions were observed namely hydrogen bonds, hydrophobic, ionic and water
bridges. H-bonds fall into four groups: backbone acceptor; backbone donor; side-chain acceptor
and side-chain donor.
H-bonds play an obvious part in ligand binding and this sort of interaction is a wellconsidered property in drug design due its effect on drug selectivity and biotransformation. To
monitor H-bonds between ligand and protein we set up the distance between the donor and
acceptor atoms (D—H···A) to be less than 2.5Å. The donor-hydrogen-acceptor (D—H···A)
angle was set up to be ≥120° and ≥90°.
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The second important interactions are hydrophobic contacts that are of three subtypes: πcation, π-π, and other non-specific interactions. Usually these interactions take place between
hydrophobic ligand fragment and a hydrophobic amino acid and/or an aromatic (Figure 4.224.26).

Figure 4.17. L-RMSF of the CDK1 ligand. The 2D ligand structure with atom labels is shown
above. The 'Fit Ligand on Protein' line shows the ligand fluctuations with respect to the protein.
The protein–ligand complex is first aligned on the protein backbone and then the ligand RMSF is
measured on the ligand heavy atoms. 'Ligand' line shows fluctuations where the ligand in each
frame is aligned on the ligand in the reference frame, and its fluctuations are measured for the
ligand heavy atoms. These RMSF values reflect the internal atom fluctuations of the ligand.
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Figure 4.18. L-RMSF of the CDK5 ligand. The 2D ligand structure with atom labels is shown
above.

Figure 4.19. L-RMSF of the GSK-3α ligand. The 2D ligand structure with atom labels is shown
above.
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Figure 4.20. L-RMSF of the GSK-3β ligand. The 2D ligand structure with atom labels is shown
above.

Figure 4.21. L-RMSF of the PERK ligand. The 2D ligand structure with atom labels is shown
above.
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We considered π-cation interaction between an aromatic and charged groups if the
distance between the groups is within 4.5 Å. π-π interactions are monitored when two aromatic
groups stacked face-to-face or face-to-edge. Other non-specific hydrophobic interactions take
place when side chain within 3.6 Å of a ligand's aromatic or aliphatic carbons. Ionic interactions
should occur within of 3.7 Å between two oppositely charged atoms. Water bridges are
hydrogen-bonded protein-ligand interactions mediated by a water molecule. The geometry
criteria of water bridges are a distance of 2.7 Å between the donor and acceptor atoms (D—
H···A); a donor angle of ≥110° between the donor-hydrogen-acceptor atoms (D—H···A); and an
acceptor angle of ≥80° between the hydrogen-acceptor-bonded atoms (H···A—X).

Figure 4.22. Protein–ligand contacts of the CDK1 complex. The chart is standardized over the
course of simulation with a value of 0.8, for example, meaning that for 80% of the simulation
time the specific interaction is conserved.
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Figure 4.23. Protein–ligand contacts of the CDK5 complex.

Figure 4.24. Protein–ligand contacts of the GSK-3α complex.
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Figure 4.25. Protein–ligand contacts of the GSK-3β complex.

Figure 4.26. Protein–ligand contacts of the PERK complex.
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All interactions that occur more than 10% of the simulation time are represented (Figures
4.27-4.31). CDK1 shows H-bond of 100%, 95% and 58% between Glu81, Leu83 and Lys33 and
ligand. In CDK5, Cys83, Glu81 and Phe80 form H-bonds with 87%, 72% and 36%. GSK-3α
shows H-bonds between the following amino acids and ligand: Lys30 with 90% and Arg86 with
49%, Thr83, Pro81, and Gln17 through water bridges with 57%, 52%, and 30% respectively.
GSK-3β exhibits H-bonds with Asp133 of 92%, and Lys85 of 73%. PERK shows H-bonds with
Gln888 of 99%, and Cys890 of 97%, and with Val651 and Val952 through water bridges of 69%
each.

Figure 4.27. Protein–ligand contacts of CDK1
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Figure 4.28. Protein–ligand contacts of CDK5
178

Figure 4.29. Protein–ligand contacts of GSK-3α

Figure 4.30. Protein–ligand contacts of GSK-3β
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Figure 4.31. Protein–ligand contacts of PERK

We also studied a timeline demonstration of the interactions and contacts for each protein
(Figures 4.32-4.36). Some of the interacting residues show more than one specific contact with
the ligand. A dial plot accompanies each rotatable bond and bar plots of the same color. We used
the ligand torsions to monitor the conformational evolution of every rotatable bond in the ligand
during the simulation trajectory. Dial plots describe the torsional conformation throughout the
course of the simulation with the beginning of the simulation is in the center and the time
evolution is plotted radially outwards. The bar plots summarize the data on the dial plots, by
showing the probability density of the torsion (Figures 4.38-3.41).

180

Figure 4.32. Protein–ligand timeline representation of CDK1. The top section shows the entire
number of the contacts protein makes with ligand over the progression of simulation. The bottom
section shows residues interacting with the ligand in each trajectory frame.
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Figure 4.33. Protein–ligand interaction timeline representation of CDK5.

Figure 4.34. Protein–ligand interaction timeline representation of GSK-3α.
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Figure 4.35. Protein–ligand interaction timeline representation of GSK-3β.

Figure 4.36. Protein–ligand interaction timeline representation of PERK.
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Figure 4.37. A 2D schematic representation of the ligand in CDK1 is shown with color-coded
rotatable bonds.
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Figure 4.38. A 2D schematic representation of the ligand in CDK5, using radial and bar plots.

185

Figure 4.39. A 2D schematic representation of the ligand in GSK-3α, using radial and bar plots
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Figure 4.40. A 2D schematic representation of the ligand in GSK-3β, using radial and bar plots
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Figure 4.41. A 2D schematic representation of the ligand in PERK, using radial and bar plots
We monitored the ligand properties throughout the course of simulation such as ligand RMSD
188

with respect to the reference conformation, radius of Gyration (rGyr) to quantify the
'extendedness' of the ligand, ligand intramolecular hydrogen bonds (intraHB), molecular surface
area (MolSA) (equivalent to a van der Waals surface area), solvent accessible surface area
(SASA), and polar surface area (PSA) (Figures 4.42-4.46). SASA is the surface area of the
ligand, which is accessible by water molecules while PSA is SASA of the ligand, which is only
controlled by oxygen and nitrogen atoms.

Figure 4.42. Ligand properties of CDK1

189

Figure 4.43. Ligand properties of CDK5

Figure 4.44. Ligand properties of GSK-3α
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Figure 4.45. Ligand properties of GSK-3β

Figure 4.46. Ligand properties of PERK
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We studied the protein-protein interaction between CDK5 and p25, and averaged their
contacts throughout the course of the 50 ns simulations. CDK5 (PDB code: 3O0G) is a dimer of
kinase-p25 complex. In our study we used one kinase chain (chain B) and one p25 chain (chain
E). The interacting amino acids are selected in a threshold distance of 8 Å. The contacts between
the kinase and p25 are checked before and after simulations and more than 70% of the contacts
were found to be preserved in all trajectory frames, which are not necessarily existed in the
reference. We are presenting here the contacts between the kinase domain and p25 (Figure 4.47),
the interaction overview (Table 4.1), H-bonds of the reference frame (Table 4.2) and of the
average frames (Table 4.3) and the contact maps (Figure 4.48)

Figure 4.47. The kinase domain is shown as violet surface and p25 as pink surface. The interface
is shown in dark color.
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Table 4.1. Interaction overview between the kinase domain and p25.
Title

Value

Number of interacting residues chain B

54

Number of interacting residues chain E

60

Number of hydrophilic-hydrophobic interactions

145

Number of hydrophilic-hydrophilic interactions

101

Number of hydrophobic-hydrophobic interactions

72

Table 4.2. H-Bonds of the reference frame.
Acceptor

Donor

Dist*

Type

Res1

Atom

Chain

Res2

Atom

Chain H-Bonds

Cat*

Dist†

SER46

OG

B

SER235

OG

E

2.65

SS

5.39

SER47

OG

B

ILE241

O

E

2.33

SM

6.08

ARG149

NH1

B

MET237

O

E

3.18

SM

7.75

ARG149

NH2

B

MET237

O

E

3.05

SM

7.75

CYS157

SG

B

ASN239

OD1

E

3.64

SS

7.00

SER235

OG

E

SER46

OG

B

2.65

SS

5.39

SER269

OG

E

GLU57

OE2

B

2.58

SS

7.28

Dist* Distance between donor and acceptor atoms in Å. Dist† Distance between Cα atoms of the
interacting residues in Å. Cat* category, SS: sidechain to sidechain H-bond, SM: sidechain
mainchain H-bond.
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Table 4.3. Average H-Bonds of all frames.
Acceptor

Donor

Dist*

Type

Res1

Atom

Chain Res2

Atom

Chain H-Bonds

Cat*

Dist†

LYS254

NZ

E

ASP38

OD2

B

2.55

SS

11.09

SER242

OG

E

VAL44

O

B

2.92

SM

5.83

ARG50

NE

B

SER235

O

E

2.95

SM

6.08

ARG50

NH2

B

GLU240

O

E

2.69

SM

11.22

LYS56

NZ

B

SER269

OG

E

2.92

SS

7.14

SER269

OG

E

GLU57

OE2

B

2.73

SS

6.86

ASN121

ND2

B

ALA277

O

E

3.11

SM

5.00

ARG149

NH1

B

MET237

O

E

2.91

SM

5.29

GLY152

N

B

ASN276

OD1

E

2.85

MS

3.87

ILE153

N

B

ASN276

OD1

E

3.02

MS

6.16

Dist* Distance between donor and acceptor atoms in Å. Dist† Distance between Cα atoms of the
interacting residues in Å. Cat* category, SS: sidechain to sidechain H-bond, SM: sidechain
mainchain H-bond, MS: mainchain sidechain H-bonds.
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Figure 4.48. Contact maps of the kinase domain (chain B) and p25 (chain E). All amino acids
that are within the cutoff distance are displayed with distance color-codes (left). All interacting
amino acids within an 8 Å cutoff are shown, color-coded based on the interaction property
(right).
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4.4. Summary
We defined the protein-ligand interaction profiles of CDK1, CDK5, GSK-3α, GSK-3β
and PERK operating MD simulations, which provided a time-dependent study of the interactions
and contacts for each ligand. These interactions included hydrogen bonds, hydrophobic, ionic,
water bridges, π-cation interaction and π-π interactions. We used the 3D models that we
generated for CDK1 and GSK-3α, and experimental X-ray crystal structures of CDK5, GSK-3β
and PERK. We monitored the ligand properties throughout the course of MD simulation
including intraHB, MolSA, SASA, and PSA. In addition, we described the protein-protein
interactions between CDK5 and p25 and reported all interacting amino acids that are within a
distance of 8 Å. Small molecules which target this interaction may offer a therapeutic benefit for
AD.
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CHAPTER 5. VIRTUAL SCREENING TO FIND INHIBITORS OF PROTEIN KINASES TO
MANAGE ALZHEIMER’S DISEASE

Manal A. Nael and Robert J. Doerksen
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5.1. Introduction
We are interested in developing new AD hits by targeting some of the kinases
significantly involved in the disease; these would be kinases that are involved in the four primary
processes relevant to the neurodegeneration found in AD, including APP processing, tau
hyperphosphorylation, neuroinflammation, and neurotoxicity. The protein kinases such as
GSK3α/β, PKC-ε, PERK, CDK1 and CDK5 are involved in tau hyperphosphorylation, APP
processing, and apoptosis. Our main intention in this chapter was to screen for inhibitors of the
protein kinases involved in AD pathogenesis. We constructed a non-redundant database from the
commercially available ZINC database through filtering the database using multiple drug-like,
functional groups and physicochemical properties filters. The constructed database was used in a
ligand-based virtual screening approach to find new PERK inhibitors using the bioactive
conformation of GSK2606414213 and based on the 3D Shape similarity searching and pose fitting
approaches. We also performed a protein structure-based virtual screening to find multiplekinase (CDK1, CDK5, and GSK-3α/β inhibitors through a parallel docking approach. In
addition, we defined two possible bryostatin 1 PKC-ε binding pockets, with druggability scores
of 0.59 and 0.47 using fpocket283 (a geometry-based cavity detection algorithm). We checked the
binding mode of bryostatin 1 in both pockets (using the FRED exhaustive search docking
algorithm) and it showed good fitting into both pockets with comparable ChemGauss4 scores (–
8.1 and –7.9). We used these structural findings as the basis for screening a library of compounds
in order to find new potent and selective PKC-ε activators.
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5.2. Methods
5.2.1. Database collection
We used the ZINC databases328 of small organic molecules and natural products in the
virtual screening. ZINC (acronym for ZINC is not commercial) is a free database for ligand and
structure based virtual screenings that contains more than 22 Million compounds in 3D format.
ZINC uses 10 vendor catalogs for the compounds’ source including ChemBridge, ChemDiv,
Ryan, Asinex, Sigma-Aldrich, Maybridge, Specs, Comgenex, and Otava. All purchasable ZINC
databases of small molecules were downloaded from http://zinc.docking.org/subsets/allpurchasable in SDF format (~22 Million compounds).
Because of the fact that over a third of all drugs are natural products329 or similar to
natural products, we decided to use also the ZINC database of natural products. We downloaded
the compounds from http://zinc.docking.org/browse/catalogs/natural-products in SDF format and
we ended up with a total number of compounds of 166210 grouped based on their vendors as
follow: AfroDb Natural Products (885 compounds), Ambinter Natural Products (36057
compounds), AnalytiCon Discovery NP (11247 compounds), Herbal Ingredients In-Vivo
Metabolism (663 compounds), Herbal Ingredients Targets (802 compounds), IBScreen NP
(74940 compounds), Indofine Natural Products (144 compounds), NPACT Database (1423
compounds), Nubbe Natural Products (588 compounds), Princeton NP (14084 compounds),
Selleck BioChemicals NP (136 compounds), Specs Natural Products (651 compounds), TCM
Database @ Taiwan (24117 compounds), and UEFS Natural Products (473 compounds).
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5.2.2. Database filtration
The molecular structures of ZINC databases328 were filtered to discard all structures that
do not fulfill the drug-likeness properties and eliminate compounds that may adversely affect
human body. Generally, we performed two major database filtration steps: (state the two here).

5.2.2.1. Drug-like filters
The stereochemical features of each structure were provided from the source. Before
generation of the 3D structures and multiple-conformers of each molecule, we filtered out all
metabolically-unstable or metabolically-unfavorable structures. We kept only structures that
fulfill our specified drug-like properties (Table 5.1). The databases were filtered using the filter
module of OpenEye Scientific software (embedded in OMEGA)330-334. Several physicochemical
properties and functional groups rules were designated to prepare our non-redundant database of
drug-like compounds (Table 5.1).

Table 5.1. Physicochemical properties used for database filtration.
Property
Minimum molecular weight
Maximum molecular weight
Minimum number of heavy atoms
Maximum number of heavy atoms
Minimum number of ring systems
Maximum number of ring systems
Minimum atoms in any ring system
Maximum atoms in any ring system
Minimum number of rotatable bonds
Maximum number of rotatable bonds
Minimum number of rigid bonds
Maximum number of rigid bonds
Minimum number of hydrogen-bond donors
Maximum number of hydrogen-bond donor

Filter Limit
200.0
700.0
15.0
35.0
0.0
5.0
0.0
20.0
0.0
20.0
0.0
35.0
0.0
6.0
200

Minimum number of hydrogen-bond acceptors
Maximum number of hydrogen-bond acceptors
Minimum number of hydrogens on O & N atoms
Maximum number of hydrogens on O & N atoms
Minimum number formal charges
Maximum number of formal charges
Minimum sum of formal charges
Maximum sum of formal charges
Minimum chiral centers
Maximum chiral centers
Minimum XLogP
Maximum XLogP
Minimum solubility
Maximum number of Lipinski violations

0.0
10.0
0.0
5.0
0.0
3.0
-2.0
2.0
0.0
5.0
1.0
4.0
Moderately
1.0

5.2.2.2. Removing molecules with undesirable functional groups
Based on functional group knowledge, undesirable functional groups were removed.
These functional groups included toxic functionalities, groups with a high chance of binding
covalently with biological targets, groups that may affect with the experimental assay, and
groups of low likelihood of oral bioavailability.

5.2.3. Generation of multiple conformers
The conformational search was performed using OMEGA of OpenEye software330-334.
OMEGA provides three force fields; the MMFF94s force field (the 94s variant of the Merck
Molecular force Field), the MMFF94s_NoEstat force field (includes all MMFF94s terms except
Coulomb interactions) and the MMFF94s_Trunc force field (includes all MMFF94s terms except
Coulomb interactions and the attractive part of Van der Waals interactions). OMEGA performs
conformer generation through two stages: model building (initial molecular structures are
generated using fragment templates) and torsion search (conformers generation based on torsion
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angles and connection between fragments). We generated multiple conformers’ database using
the following parameters.

5.2.3.1. Force field
We used MMFF94s_NoEstat (the 94s variant of Merck molecular force field excluding
the columbic terms from the MMFF94s force field) as the build and search fore fields.

5.2.3.2. Energy window
We used an energy window of 10 kcal/mol as the maximum allowed energetic separation
from the lowest conformer energy in the model building and torsion search stages. Any
conformer that has calculated strain energy less than the sum of the energy window and the
energy of the global minimum conformer was accepted. Higher energy conformers were
discarded.

5.2.3.3. Root Mean Square Deviation (RMSD) and rotatable bonds
We specified the Cartesian distance (RMSD) below which two conformers are
considered duplicates as 0.5 Å. The maximum number of rotatable bonds was set to -1 to allow
for no maximum limit.
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5.2.3.4. Maximum number of conformers
The maximum number of conformations to be generated was set to zero to allow for
generation of all possible conformers within the specified energy window and RMSD. All
generated conformers were written to the output file. Duplicates were removed.

5.2.3.5. Structure enumeration
We allowed for enumeration of pyramidal invertible nitrogen geometries, and ring
conformers. We did not consider for sampling the hydrogen positions for -OH, -SH, and amines.

5.2.4. 3D similarity search
In our study we performed a 3D similarity search using a combined 3D shape model and
pharmacophoric elements of the bioactive conformer of GSK2606414213. We carried out the
study according to the following steps:

5.2.4.1. 3D similarity model construction
The bioactive conformer of GSK2606414213 was extracted from the crystal structure of
the protein kinase RNA-like endoplasmic reticulum kinase (PERK; PDB ID: 4G31213) by using
Openeye software335,

336

. 3D shape query with color atoms (pharmacophoric elements) was

constructed by vROCS335, 336. We used ligand model builder to create the shape query, allowing
more than model to be generated and merging the color atoms with the 3D shape to assure that
the shape query codes both molecular shape and chemical features. We used Mills Dean force
field as the color force field to build and then measure chemical similarity between the query and
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the molecular database and as well to refine the shape-based overlays in the similarity search
step335, 336. In general, the color force field file describes color atoms type to specify: which
functional groups the color atoms should be applied to (hydrogens are ignored), and the type of
interaction between color atoms (attractive or repulsive). The color features include: donor such
as acid-OH, acceptor such as carboxylate, anion such as tetrazole, cation as guanidinium,
hydrophobe as alkyl groups, and rings which are of defined size e.g. 4-7 atoms.

5.2.4.2. 3D similarity model validation
We constructed a dataset of actives and decoys based on the reported IC50 values for the
purpose of statistically validating the query for its ability to discriminate between active and
inactive molecules. The database molecules were downloaded from the binding database337
(http://www.bindingdb.org/bind/index.jsp) as well as sketched from literature (Table 5.2).
Compounds having IC50 values up to 250 nM are considered active and above 1000 nM are
considered inactive. We checked the molecular similarity of the active and inactive sets in terms
of molecular scaffold, molecular weight, calculated logP to increase the confidence that the
query is truly selective. The database was cleaned and duplicates were removed using canvas.
We generated multiple conformers for each molecule using OMEGA with the following
parameters: zero value for maximum number of conformers to ensure thorough conformational
search without limiting the number of conformers, MMFF94s_NoEstat as search and 3D build
force field, energy window of 10 kcal/mol, and the maximum number of rotatable bonds was set
to -1 to allow for no maximum limit.
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Table 5.2. Actives and decoys datasets.
Dataset
Actives
Decoys

Number of compounds
47
18

Number of conformers
71393
92052

IC50 (nM)
0.2-250
1000-10000

We performed model validation with vROCS335, 336 considering TanimotoCombo score
for ranking, which is a combination between Tanimoto shape score (shape complementarity) and
Tanimoto color score (common chemical features).
The following is the list of structures that we used in our validation step. The structures
are diverse enough to account for all PERK inhibitors’ scaffolds213, 338-344 and to provide a good
validation output.

205

N

O

O

R

N

OEt

R=

NH

(6800 nM)

N

(820 nM)

O

Furopyridine inhibitors (indanone analogs)

N

O
R
NH

O

N
N
H

R=

N

(1300 nM),

(18nM)

NH
HO N

Furopyridine inhibitors (hydroxyamidines analogs)

N

O

O

N

R

R=

NH

N
H

N

(7800 nM),

(1100 nM)

O
NH(CH) 2NHCH 3
N
NH

(4600 nM)

Furopyridine inhibitors (pyrazole analogs)

206

N

O
CO2Et

R

IC50 (nM)
5000

N

NH
R

NH 2

9100

OH

54

142

OH
F

N

R

O
R

IC50 (nM)
86.7

O
N
H

NH

102

O
NH(CH) 2N(CH 3)2
HO

4.1

N
N

O

142

N
N
H

N

N

16

N
N

N

207

R

O

N

IC50 (nM)
823

O

R

N
H

NH

O
N
H

OH
Cl

556

N
N

31

N
N

1870

O
NH(CH) 3NMe 2

442

O
OEt

OH

O N

HN

N R1

O
HO

R1
CH3
CH3
CH3

O

O

R2

O

O
NH 2
H 2N

N

N
H

N

IC50 (nM) >10000
O

N

O
O
N

O

O
N
H
NH

N

IC50 (nM) >1000
208

R2
NO2
N(Me)2
NHCH(CH3)2
N(CH3)2

IC50 (uM)
>10
>10
>10
>10

O

N

R5
NH
R1

R4
N

R2
R3

R1
H

R2
H

R3
H

R4
H

Cl

H

H

H

Cl

N
H

R5
N

IC50 (nM)
2500

H

N

250

H

H

N

1600

Cl H
Me H

H
H

H
H

F

H

H

Cl

CONHCH(CH3)2
N

4200
840

H

N

3500

Me H

H

N

300

Cl

H

H

Et

N

140

Cl

H

H

(CH2)
3NH2

N

1300

Cl

H

H

(CH2)
3OH

N

350

209

R1

O

R2
N

IC50 (nM)
3.2

N

1.2

R1
N

1.9

NH 2
N

N
H

S

0.9

H
N

R2

N

1.3

N
N

F

H

11.7

H

2.5

F

F
O
N
F

NH 2
N

X
Z

Y

X
CH
CH
CH
N
CH

Y
S
O
O
N-CH3
N-CH3

Z
N
N
CH
N
N

IC50 (nM)
0.6
7.4
8.1
5.4
0.4

2,3-dihydro-1H-indol-5-yl}- 1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
2,3-dihydro-1H-indol-5-yl}- furo[3,2-c]pyridin-4-amine
2,3-dihy- dro-1H-indol-5-yl]thieno[3,2-c]pyridin-4-amine

210

R1

R1
F
H
H
CH3
H
H
Cl
H
H
H
H
F

R2

O
N

R3
R4

NH 2
N
N

R1

N

R2
N N

H
N

N
N

R2
H
F
H
H
CH3
H
H
Cl
OCH3
CF3
CF3
F

R3
H
H
F
H
H
CH3
H
H
H
H
H
H

R4
H
H
H
H
H
H
H
H
H
H
F
F

IC50 (nM)
0.7
0.2
1.5
0.2
0.2
17.4
0.9
0.2
0.5
0.4
0.3
0.2

R3
NH
O

R1
O
S
N
O

R2
CH3

R3
IC50 (nM)
CH3 >10000

CH3

H

>10000

CH2CH2OH H

>10000

CH3

>10000

N
O

N
O

N
N
O
F

F

F

N
O

211

H

R

O

R
N

X IC50 (nM)
H 19.1

N

H 23.4

N

NH 2

X

N
N

N

H 63.8

N

H 2.5
N

F

0.8

N

H 0.5
N
CF 3

F

0.5

N
CF 3

H 57.5
N N

H 16.6
N N

H 1.9
N N

F
N N

212

2.7

5.2.5. Collection of multiple kinases’ ligand databases
We downloaded 1100 CDK1 inhibitors, 1100 CDK5 inhibitors, 300 GSK-3α inhibitors,
and 1700 GSK-3β inhibitors as 3D SDF files from the binding database337. We divided the
datasets into actives (all compounds that have IC50 ≤250 nM) and inactives (all compounds that
have IC50 ≥1000 nM).
We used LigPrep345 to prepare the databases using OPLS2005 forcefield and charges. We
enumerated all possible protonation and ionization states for each ligand using Ionizer at a pH of
7.4. The stereoisomers were generated if not assigned with a limit of 32 stereoisomers per ligand.
We generated all possible tautomeric states. Finally, we kept only the lowest energy conformer
for each ligand.

5.2.6. Structure-based pharmacophore modeling
To construct a structure-based pharmacophore we used MOE346. The PDB file was
loaded into MOE and prepared (correcting any problems with the structure, adding hydrogens
and assigning protonation states) using the structure preparation tool. Protonate3D was used to
fix the rotamers of -SH -OH Cys, Ser, Tyr and Thr, the ionization states of the acidic and basic
amino acid residues such as Arg, Asp, Glu, Lys, and His, and the tautomers of imidazoles (His)
and carboxylic acids (Asp, Glu). Then the pharmacophoric regions were identified as colored
annotation points based on ligand-receptor interactions. These annotation points were converted
into pharmacophoric features. The features radius was adjusted according to the position of
amino acid residues. Excluded volumes were determined based on the regions occupied by active
site amino acids.
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5.2.7. Receptor grid preparation
We used OpenEye scientific software347, 348 (www.eyesopen.com) to create the receptor
grids for CDK1, CDK5, GSK-3α and GSK-3β. The centroid of the docking box was defined
either based on bound ligands (CDK5 and GSK-3β) or the amino acid residues identified in to be
in the binding pocket (CDK1 and GSK-3α). The amino acids in the ligand binding pockets of
CDK1 and GSK-3α are described in Chapter 2. The volume and dimensions of the grid box of
each protein are defined for CDK1 as 8742 Å3 (18.33 Å x 19.33 Å x 24.67 Å), for CDK5 as 4991
Å3 (16.00 Å x 17.33 Å x 18.00 Å), for GSK-3α as 8205 Å3 (18.33 Å x 25.33 Å x 17.67 Å), and
for GSK-3β as 8292 Å3 (23.00 Å x 18.33 Å x 19.67 Å). The dimensions of the outer contour of
the docking region was determined for CDK1, CDK5, GSK-3α and GSK-3β as 2096 Å3, 368 Å3,
1686 Å3, and 667 Å3 respectively. In grid preparation we did not impose any kind of constraints.

5.2.8. Ligand binding pocket detection for PKC-ε
We used the geometry-based pocket detection algorithm283 (fpocket) to detect the valid
ligand binding pocket of PKC-ε. We prepared the protein to determine the alpha sphere for
distance-based clustering. All small polar clusters were discarded before defining the valid
protein cavities. The pockets are ranked using the druggability score. Then we used OpenEye
scientific software to create the receptor grid for docking347, 348.
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5.2.9. Virtual screening for PERK modulators
In order to identify new hits as PERK inhibitors, we performed a combined ligand and
structure-based virtual screening, starting with 3D similarity search with ROCS335, 336 followed
by pose fitting application349.

5.2.9.1. Ligand-based virtual screening (ROCS similarity search)
The prepared drug-like database of Zinc Natural Products was searched against the
ROCS335,

336

query with and without considering a search cutoff. The search cutoff was

determined from the validation step to be a TanimotoCombo score of 1.0 based on the scores
distribution of the actives and decoys. This TanimotoCombo score was used to rank the resulting
hits. The results of each run were used in the next step of pose fitting.

5.2.9.2. Protein structure-based virtual screening (Pose fitting)
To reduce the number of hits returned from pervious steps, we used POSIT349 to fit
ligands within the active site occupied by the native ligand.

5.2.9.2.1. Receptor generation
Make pose receptor module of POSIT was used to automatically generate the receptor
grid for pose fitting step. The allowed clashes between native ligand and protein amino acid
residues were set in the range of acceptable mild clashes (≥ 0.2 Å < 0.65 Å interpenetration).
Thus the resulting fits will have similar contacts with the amino acid residues as native ligand.
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5.2.9.2.2. Pose fitting
Ligand binding probabilities were calculated using POSIT. The hits resulted from the 3D
similarity search were checked for receptor fitting by allowing mid clashes same as native
ligand. The output poses were scored based on the similarity with native ligand and receptor
binding.

5.2.10. Virtual screening for multiple kinase modulators
In order to pinpoint new leads as multiple kinases inhibitors (CDK1, CDK5, GSK-3α and
GSK-3β), we prepared a multi-filter virtual screening workflow. We started with a docking
benchmark analysis to set up the cutoffs for each kinase, followed by docking filtrations,
clustering and hit selection.

5.2.10.1. Docking benchmarking
The compound databases are docking into their particular kinase using FRED of
OpenEye scientific software347, 348. Standard docking precision was used specifying 1.0 Å in
ligand translations and 1.5 Å in ligand rotations. One pose was saved for each compound.
The actives and inactives were docked using the same protocol and the docking scores were
compared to set up the cutoff for each kinase type.

5.2.10.2. Multiple docking filtration
The drug-like databases of small organic molecules and natural products were docked
sequentially into each kinase. Each kinase was considered as a filter for the second step. We
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started by docking the compounds into CDK1 using -8.5 kcal/mol as scoring cutoff. All survived
compounds were then docked into CDK5 (cutoff of -8 kcal/mol), then into GSK-3α (cutoff of -9
kcal/mol) and finally into GSK-3β (cutoff of -9 kcal/mol). The resulting compounds were then
clustered.

5.2.11. Clustering and selection of hits
We selected a set of compounds to be processed for biological testing after clustering.
The compounds were clustered using topological torsions method of CANVAS350-352.
Topological torsions are illustrated as (NPI-TYPE-NBR) - (NPI-TYPE-NBR) - (NPI-TYPENBR) - (NPI-TYPE-NBR), where NPI is the number of π electrons on each atom, TYPE is the
atomic species and NBR is the number of non-hydrogen branches.
NBR is calculated for the two end atoms as the total number of branches minus 1, and for
the two central atoms as the total number of branches minus 2. After calculating the structural
fingerprints based on topological torsions, we hierarchically clustered the compounds into 10
groups using the similarity score, which is calculated by 𝑆 = 2𝐷&W /(𝑑& + 𝑑W ) where di and dj are
the number of distinct descriptors in structures i and j, and dij is the number of descriptors the
two structures have in common.

5.3. Results and discussion
We used the Zinc databases of Natural products because of the well-addressed prominent
role of plant-based systems in healthcare. Plant-derived traditional medicines are used by more
than 65% of the world population according to the world health organization (WHO)329. Plant217

derived compounds show a good example in drug discovery programs such as the development
of antimalarial drugs, in particular quinine and artemisinin, the development of the
bronchodilator chromolyn by modifying khellin from Ammi visnaga, the discovery of the
antidiabetic drug metformin from galegine, which is a compound derived from Galega of
ficinalis, and many other examples including verapamil, morphine and codeine from related
compounds isolated from Papaver somniferum329. Most of the isolated compounds from natural
sources violate the roles of drug-likeness, this why we need to curate the structural database first
before going into computational expensive steps. Ligand preparation is a crucial step in computer
aided drug design process. All ligands’ atoms were adjusted for charges and atom types during
the filtration step. In order to start with a more drug-like database, several drug filters have been
applied to eliminate all compounds that may have reactivity issues, unfavorable metabolic
pathways, or poor bioavailability. Several criteria have been used to filter the large database into
a drug-like one including; 1) Physical properties such as molecular weight, topological polar
surface area (TPSA), and logP. 2) Bioavailability, such as atomic and functional group content,
absolute and relative content of heteroatoms, and limits on a very wide variety of functional
groups. 3) Molecular graph topology, such as number and size of ring systems, flexibility of the
molecule, and size and shape of non-ring chains. We started with 22,724,825 synthetic small
organic compounds and 166,210 natural product compounds. After filtration, we got 11,251,123
and 28,614 for the synthetic and natural products, respectively. The number of conformers that
were generated for each vendor natural product database is shown in Table 5.3.
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Table 5.3. The number of conformers generated for each file.
File ID
ambintnp_p0.0.sdf
ambintnp_p1.0.sdf
hitnp_p0.0.sdf
hitnp_p1.0.sdf
ibsnp_p0.0.sdf
indofinenp_p0.0.sdf
indofinenp_p1.0.sdf
npactnp_p0.0.sdf
npactnp_p1.0.sdf
princetonnp_p0.0.sdf
princetonnp_p1.0.sdf
sellecknp_p0.0.sdf
sellecknp_p1.0.sdf
specsnp_p0.0.sdf
specsnp_p1.0.sdf
tcmnp_p0.0.sdf
tcmnp_p1.0.sdf
uefsnp_p0.0.sdf
uefsnp_p1.0.sdf

# Compounds
4901
7
85
3
18571
24
2
217
11
1931
642
19
3
109
14
1858
111
97
9

# Conformers
74225645
196
470730
9
187214251
172272
35884
867349
68596
22619734
6925254
16017
4347
274353
6734
10568304
299922
301088
7974

To search for new PERK inhibitors, we used GSK2606414 (Figure 5.1) as a guide in our
virtual screening protocol (Figure 5.2). We used the Zinc databases to prepare drug-like ones to
use them through two different initial filters: 3D similarity and pharmacophore-based ones. Then
the resulting compounds are pose fitted in PERK binding site using the structural information of
the pocket and the bound ligand. The compounds are then clustered and 10 compounds are
selected for biological testing.
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Figure 5.1. Cartoon representation of PERK (PDB 4G31, right), helices are shown in red, beta
sheets in yellow, loops in green and the ligand is shown in grey. GSK2606414 structure (left).

Figure 5.2. Virtual screening workflow of PERK inhibitors. The ZINC databases pass through
drug-like filters, then through shape and pharmacophore based filters, before being tested for
fitting inside PERK receptors. Ten compounds were selected for biological screening after
clustering.
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The results of model validation showed an AUC (area under the curve) of 0.865 (mean
value 95% confidence limits) (Table 5.3, and Figure 5.3) indicating that the query is predictive
and will be able to separate actives from decoys. We changed the ranking score from
TanimotoCombo to ShapeTanimoto, and the AUC has changed to 0.842 indicating that shape
alone is a less selective tool to identify PERK actives from decoys and that colors
(pharmacophoric elements) are an important addition to the query. We also used Tanimoto color
to score compounds and the AUC has changed to 0.924 indicating the importance of common
chemical features in discriminating between actives and decoys. The enrichment percentages at
the following values: 0.5%, 1% and 2% were reported (Table 5.3). The formulation of
enrichment that is used in ROCS is the ratio of true positive rates to the false positive rates of
0.5%, 1% and 2%. Thus enrichment at 1% is the fraction of actives seen along with the top 1%
of known decoys (multiplied by 100). We plotted the fraction of actives found on the Y-axis
versus the fraction of decoys on the X-axis in ROCS curve to define the cutoff of
TanimotoCombo score that we will use in the virtual screening. In ROCS curve the top scoring
compounds are plotted closest to the origin. As well, we plotted the score Histogram as colorcoded histograms for the score distribution of the actives and decoys (Figure 5.4). Active
compounds showed a distribution with higher frequency of obtaining a high score (i.e. further to
the right of the plot). Based on that distribution, we set a cutoff for TanimotoCombo of 1.0 to be
used in the virtual screening.
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Table 5.4. Model statistical validation parameters.
Statistical Parameter

Significance

AUC
0.5% Enrichment
1.0% Enrichment
2.0% Enrichment

0.865
152.8
74.5
38.3

Figure 5.3. The ROCS curve (top). The color-coded histograms (bottom).
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As another filter we constructed a structure-based pharmacophore with MOE using the
structural information from the PDB file of PERK in complex with GSK2606414. The
pharmacophoric elements and excluded volumes were built and adjusted according to the
surrounding amino acid residues (Figure 5.4). The constructed pharmacopphore was based on the
protein-ligand interaction fingerprint of PERK- GSK2606414 complex and it has five elements;
one hydrophobic centroid or aromatic center, two hydrophobic and two aromatic centroids
(Figure 5.5). Also, it has multiple excluded volumes based on the occupied sites of the binding
pocket. The pharmacophore contains one site for hydrogen bond donor and one site for acceptor
(Figure 5.4). In the screening step we permitted partial matching of at least three features.

Figure 5.4. Left, the pharmacophore model features: green for hydrophobic (Hyd), orange for
aromatic (Aro), cyan for hydrogen bond acceptor (Acc) and purple for donor (Don). Right, the
pharmacophore model with the excluded volumes as grey surface.
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Figure 5.5. The pharmacophoric elements and the spatial distances between them.

The resulting compounds from the shape- and pharmacophore-based screening of ZINC
databases were passed into a more rigorous hit filtration step in POSIT of OpenEye. POSIT
works by finding initial poses by exhaustive and discarding all clashing poses. The poses are
then selected based on the information extracted from bound ligand, and then the poses are
scored relative to native ligand. We kept all compounds that have more than 42% probability of
similar binding to native ligand. The shape screening and pharmacophore searching of natural
products resulted in 31 (Figure 5.6) and 340 compounds, respectively. For the ZINC database of
synthetic compounds, we considered that all compounds should have ≥1.00 TanimotoCombo
score in shape and ≤0.7 Å in pharmacophore-based screening. We kept the top 2000 ranking
compounds after pose fitting. Canvas module of Schrödinger was used to calculate the binary
structural fingerprints from the 2D structures for cluster analysis to select compounds for
biological testing (Figures 5.6-5.10).
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Figure 5.6. The resulting compounds from virtual screening after pose fitting shown as grey
sticks.

Figure 5.7. Selected examples of the compounds selected for biological testing compared to the
native ligand (which is first to the left).
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Figure 5.8. Examples of selected compounds showing how they fit well in the regions of
negative and positive free energy.
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Figure 5.9. Examples of selected compounds interacting with the calculated water molecules in
the binding site. The upper two panels show seven waters and how they form hydrogen bonds
with the surrounding amino acids and native ligand. The other panels show selected compounds
and how they interact with these calculated waters.
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Figure 5.10. Compounds selected for biological testing after pharmacophore screening.
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To search for new multiple kinase’ inhibitors, we planned a multi-layer virtual screening
workflow (Figure 5.11).

ZINC Databases
Drug-like database

Filtration
CDK1-based
screening

CDK1
Best Scoring Compounds
CDK1 and CDK5

CDK5-based
screening

Best Scoring Compounds
CDK1, CDK5 and GSK-3α
Best Scoring Compounds
CDK1, CDK5, GSK-3α
and GSK-3β
Best Scoring Compounds

Clusters

GSK-3α based
screening

GSK-3β based
screening

Fingerprinting

Selection

Testing

Figure 5.11. Virtual screening workflow for multiple kinases’ inhibitors.
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We filtered all ZINC databases using drug-like filtration rules. The constructed drug-like
libraries were docked into CDK1 to generate a library of proposed CDK1 binders. The CDK1
binders are then docked into CDK5, then to GSK-3α and GSK-3β to end with binders to all
screened kinases. In the first step we retained ~11 Million compounds in the drug-like database.
CDK1-based screening resulted in ~ 80,000, CDK5 in 40,000, GSK-α in 8000 and GSK-3β in
500 compounds. Then we selected 10 compounds after clustering. The cutoff for each docking
step was established during the benchmark analysis using active and inactive compound datasets.
The number of compounds and activity ranges are described under the methodology section.
Based on the benchmarking, we selected which model to use for CDK1 and GSK-3α, and a
suitable PDB file for CDK5 and GSK-3β. The resulting compounds from these steps showed
interesting interaction models. For example ZINC77470457 showed hydrogen bonding with the
conserved Lys of CDK1 and Asp of the DFG region. Several calculated waters are observed ≤4
Å around the ligand (Figures 5.11 and 5.12).

Figure 5.11. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with
CDK1. Waters are shown as spheres colored red (∆G>0) to green (∆G<0).
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ZINC484412812 interacts with the hinge region and conserved Lys of CDK1 (Figures
5.11 and 5.13). Some waters are displaced by the ligand (Figure 5.13). In CDK5, ZINC77470457
forms hydrogen bonds with the hinge and with Asp of the DFG motif (Figure 5.14 and 5.15).
ZINC484412812 forms one hydrogen bond with the conserved Lys and three with the hinge
(Figure 5.14 and 5.16). Several waters are displaced by the ligands (Figures 5.17 and 5.18). In
GSK-3α, ZINC77470457 forms hydrogen bonds with the conserved Lys and the hinge (Figures
5.17 and 5.18) while ZINC484412812 forms salt bridge with Asp of the DFG region, hydrogen
bonds with DFG-1 and the conserved Lys (Figures 5.17 and 5.19). The ligands displace several
water molecules in the active site (Figures 5.18 and 5.19). For GSK-3β, ZINC77470457 shows
hydrogen bonding interactions with the conserved Lys and GK+2 (Figures 5.20 and 5.21), while
ZINC484412812 shows interactions with GK+3 and GK+4 (Figures 5.20 and 5.22). Several
waters are observed around the ligand.

Figure 5.12. 2D interaction model of ZINC77470457 with CDK1. Waters are shown as spheres
colored red (∆G>0) to green (∆G<0).
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Figure 5.13. 2D interaction model of ZINC484412812 with CDK1. Waters are shown as spheres
colored red (∆G>0) to green (∆G<0).

Figure 5.14. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with
CDK5. Waters are shown as spheres colored red (∆G>0) to green (∆G<0).
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Figure 5.15. 2D interaction model of ZINC77470457 with CDK5. Waters are shown as spheres
colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are displaced
by the ligand.

Figure 5.16. 2D interaction model of ZINC484412812 with CDK5. Waters are shown as spheres
colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are displaced
by the ligand.
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Figure 5.17. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with
GSK-3α. Waters are shown as spheres colored red (∆G>0) to green (∆G<0).

Figure 5.18. 2D interaction model of ZINC77470457 with GSK-3α. Waters are shown as
spheres colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are
displaced by the ligand.
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Figure 5.19. 2D interaction model of ZINC484412812 with GSK-3α. Waters are shown as
spheres colored red (∆G>0) to green (∆G<0). The water molecules that are marked with X are
displaced by the ligand.

Figure 5.20. 3D interaction models of ZINC77470457 (left) and ZINC484412812 (right) with
GSK-3β. Waters are shown as spheres colored red (∆G>0) to green (∆G<0).
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Figure 5.21. 2D interaction model of ZINC77470457 with GSK-3β. Waters are shown as
spheres colored red (∆G>0) to green (∆G<0).

Figure 5.22. 2D interaction model of ZINC484412812 with GSK-3β. Waters are shown as
spheres colored red (∆G>0) to green (∆G<0).
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Figure 5.23. Compounds selected for testing against CDK1, CDK5 and GSK3α/β.

We prepared a third virtual screening workflow for PKC-ε modulators (Figure 5.24). Our
objective is to find new enzyme activators. It is reported that Bryostatin 1 (an PKC-ε activator)
binds to C1B domain of the enzyme. The drug-like compounds of ZINC database were screened
with structural similarity filter (≥50% to benzolactam fragment). The resulting compounds
(~5000) were then docked into C1B domain. Then we clustered the compounds and selected 6
compounds for testing. The possible ligand binding pockets of the C1B domain are defined using
geometry-based cavity detection algorithm, fpocket283 (Figure 5.25). To validate the pockets, we
docked Bryostatin 1 in both pockets (Figures 5.26-5.27). The pocket filled with cyan spheres
(Figure 5.25) shows higher druggability score (0.59) than the one with purple spheres (0.47).
Bryostatin 1 showed good fitting in both pockets with comparable ChemGauss4 score (-8.1 and -
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7.9). The selected compounds showed hydrogen bonding and hydrophobic interactions with the
surrounding amino acids (Figure 5.28).

Figure 5.24. Virtual screening workflow for PKC-ε modulators.
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Figure 5.25. The 3D model of C1B of PKC-ε (left). Right: the detected ligand-binding pockets
of C1B of PKC-ε. Pocket 1 is the one filled with cyan spheres. Pocket 2 is the one filled with
purple spheres.

Figure 5.26. The binding mode of Bryostatin 1 in pocket 1

Figure 5.27. The binding mode of Bryostatin 1 in pocket 2
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Figure 5.28. The 2D interaction models of potential PKC-ε activators.
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5.4. Summary
In order to identify new modulators for protein kinases targets in AD, we implemented
three virtual screening protocols. The first protocol was a ligand and protein structure based
approach in which we filtered a drug-like database of >22 millions compounds through two
molecular filters: a 3D-shape query and a PERK-structure based pharmacophore model, relying
on the published bioactive conformer of a PERK inhibitor which was co-crystallized with the
PERK kinase domain. Then, the binding modes of the resulting compounds were predicted and
scored using a pose-fitting approach. After clustering analysis, we obtained compounds with
high probability of inhibiting the PERK kinase. In the second protocol, protein structure-based
virtual screening was applied to find multiple-kinase inhibitors through a parallel docking
simulations into validated receptor grids of CDK1, CDK5 and GSK-3 kinases. The highly
scoring and unique compounds (based on the structural fingerprints) were selected for biological
evaluation. In the third protocol, we searched for potential activators of PKC-ε by the
implementation of a novel approach based on the structure of the C1B domain of PKC-ε and
guided by the binding mode of bryostatin to the 3D model of C1B domain.
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CHAPTER 6. FUTURE PLANS
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We presented several computational explorations to study the targeting of six essential
protein kinases in AD. The thermodynamic calculations of the active sites of these kinases
provided beneficial strategies for the improvement of ligand affinity as well as ligand selectivity.
Hence, we plan to use thermodynamic-directed lead modifications to enhance the activity of the
identified hits from our VS workflows.

Since we studied protein-protein interactions of CDK5-p25, one of the future plans is to
define the binding pockets at the interface between CDK5 and p25. Then, we will apply the
virtual screening protocol to target these protein-protein interactions using the defined pockets as
filters. This strategy would be beneficial to design novel scaffolds as AD hits, and to achieve
higher selectivity because CDK5-p25 complex is elevated significantly in AD brain.

Because there is no known small molecule activator of PKC-ε, we plan to test the hit
compounds which were identified from the virtual screening and to use a fragment-based
strategy to build libraries of analogs that can be tested as PKC-ε activators. Fragment-based
studied would emerge into synthetically feasible structures that can be synthesized or searched
for their availability in structure databases.
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